FI940105L - Menetelmä sertraliinivälituotteiden valmistamiseksi - Google Patents

Menetelmä sertraliinivälituotteiden valmistamiseksi Download PDF

Info

Publication number: FI940105L
Authority: FI; Finland
Prior art keywords: intermediates; preparing sertraline; sertraline; preparing; sertraline intermediates
Prior art date: 1991-07-11

Application number

FI940105A

Other languages

English (en)

Swedish (sv)

Other versions

FI940105A0 (fi

FI112209B (fi

Inventor

Michael Trevelyan Williams

Jr Willard Mckowan Welch

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-07-11

Filing date

1994-01-10

Publication date

1994-01-10

1994-01-10 Application filed by Pfizer filed Critical Pfizer

1994-01-10 Publication of FI940105L publication Critical patent/FI940105L/fi

1994-01-10 Publication of FI940105A0 publication Critical patent/FI940105A0/fi

2003-11-14 Application granted granted Critical

2003-11-14 Publication of FI112209B publication Critical patent/FI112209B/fi

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
- C07C233/14—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/23—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

FI940105A 1991-07-11 1994-01-10 trans-stereoisomeerinen sertraliinin välituote, menetelmä sen valmistamiseksi ja menetelmässä käytetty välituote FI112209B (fi)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB919114948A GB9114948D0 (en)	1991-07-11	1991-07-11	Process for preparing sertraline intermediates
GB9114948		1991-07-11
PCT/EP1992/001496 WO1993001161A1 (en)	1991-07-11	1992-07-03	Process for preparing sertraline intermediates
EP9201496		1992-07-03

Publications (3)

Publication Number	Publication Date
FI940105L true FI940105L (fi)	1994-01-10
FI940105A0 FI940105A0 (fi)	1994-01-10
FI112209B FI112209B (fi)	2003-11-14

Family

ID=10698171

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI940105A FI112209B (fi)	1991-07-11	1994-01-10	trans-stereoisomeerinen sertraliinin välituote, menetelmä sen valmistamiseksi ja menetelmässä käytetty välituote

Country Status (14)

Country	Link
US (1)	US5442116A (fi)
EP (1)	EP0595851B1 (fi)
JP (1)	JP2563754B2 (fi)
AT (1)	ATE132848T1 (fi)
CA (1)	CA2109818C (fi)
DE (1)	DE69207601T2 (fi)
DK (1)	DK0595851T3 (fi)
ES (1)	ES2082481T3 (fi)
FI (1)	FI112209B (fi)
GB (1)	GB9114948D0 (fi)
GR (1)	GR3019122T3 (fi)
IE (1)	IE71029B1 (fi)
PT (1)	PT100673B (fi)
WO (1)	WO1993001161A1 (fi)

Families Citing this family (856)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH08504320A (ja) *	1992-09-25	1996-05-14	コモンウエルス・サイエンティフィック・アンド・インダストリアル・リサーチ・オーガニゼーション	標的結合性ポリペプチド
ES2217748T3 (es)	1998-03-18	2004-11-01	Ciba Specialty Chemicals Holding Inc.	Procedimiento para la hidrogenacin catalitica cis-selectiva de ciclohexilidenaminas.
FR2777000B1 (fr) *	1998-04-01	2002-09-27	Catalys	Procede de preparation de la sertraline racemique
SE9801992D0 (sv) *	1998-06-04	1998-06-04	Astra Ab	New 3-aryl-2-hydroxypropionic acid derivative I
IL132500A0 (en)	1998-10-29	2001-03-19	Pfizer Prod Inc	Stereoselective microbial reduction of a racemic tetralone
WO2000025598A1 (en) *	1998-11-03	2000-05-11	Dandy A/S	Sucrose fatty acid esters for use as increased release of active ingredients
CA2450402A1 (en)	1998-12-22	2000-06-29	Genentech, Inc.	Methods and compositions for inhibiting cancer cell growth comprising pro224
AU6275900A (en)	1999-07-29	2001-02-19	Ciba Specialty Chemicals Holding Inc.	Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
DK174219B1 (da) *	1999-10-27	2002-09-30	Gea Farmaceutisk Fabrik As	Forbedret syntese af racemisk sertralin
US7056702B2 (en)	2002-12-16	2006-06-06	Kimberly Clark Co	Detecting lipocalin
MXPA05011038A (es) *	2003-04-14	2006-01-24	Teva Pharma	Hidrogenacion de compuestos intermedios de imina de sertralina con catalizadores.
EP3006466B1 (en)	2005-12-02	2018-08-01	Genentech, Inc.	Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
JP5358187B2 (ja)	2005-12-15	2013-12-04	ジェネンテック，インコーポレイテッド	ポリユビキチンを標的とする方法と組成物
PT2032606E (pt)	2006-05-30	2014-02-05	Genentech Inc	Anticorpos e imunoconjugados e respetivas utilizações
US7893053B2 (en) *	2006-06-16	2011-02-22	Theracos, Inc.	Treating psychological conditions using muscarinic receptor M1 antagonists
EP2061906B1 (en)	2006-09-12	2011-08-31	Genentech, Inc.	Methods and compositions for the diagnosis and treatment of lung cancer using pdgfra, kit or kdr gene as genetic marker
EP2061814B1 (en)	2006-10-27	2012-06-06	Genentech, Inc.	Antibodies and immunoconjugates and uses therefor
AU2008216495A1 (en)	2007-02-09	2008-08-21	Genentech, Inc.	Anti-Robo4 antibodies and uses therefor
PL2132573T3 (pl)	2007-03-02	2014-09-30	Genentech Inc	Prognozowanie odpowiedzi na inhibitor dimeryzacji HER oparte na niskiej ekspresji HER3
US7960139B2 (en)	2007-03-23	2011-06-14	Academia Sinica	Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
EP3318643A3 (en)	2007-05-21	2018-06-20	Genentech, Inc.	Methods and compositions for identifying and treating lupus
HUE061746T2 (hu)	2007-07-09	2023-08-28	Genentech Inc	Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során
EP2194066B1 (en)	2007-09-26	2016-03-09	Chugai Seiyaku Kabushiki Kaisha	Modified antibody constant region
CN103142999A (zh)	2007-11-07	2013-06-12	健泰科生物技术公司	用于治疗微生物病症的组合物和方法
TWI468417B (zh)	2007-11-30	2015-01-11	Genentech Inc	抗－ｖｅｇｆ抗體
ES2442024T3 (es)	2008-07-15	2014-02-07	Academia Sinica	Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
CA2739429C (en)	2008-10-14	2020-12-22	Lisa A. Damico	Immunoglobulin variants and uses thereof
WO2010075249A2 (en)	2008-12-22	2010-07-01	Genentech, Inc.	A method for treating rheumatoid arthritis with b-cell antagonists
AU2009329866B2 (en)	2008-12-23	2016-09-29	Genentech, Inc.	Immunoglobulin variants with altered binding to protein A
WO2010078376A2 (en)	2008-12-30	2010-07-08	Ventana Medical Systems, Inc.	Fc-specific polymer-conjugated antibodies and their diagnostic use
JP5616428B2 (ja)	2009-04-07	2014-10-29	ロシュグリクアートアクチェンゲゼルシャフト	三価の二重特異性抗体
US9676845B2 (en)	2009-06-16	2017-06-13	Hoffmann-La Roche, Inc.	Bispecific antigen binding proteins
WO2011014457A1 (en)	2009-07-27	2011-02-03	Genentech, Inc.	Combination treatments
US20110039300A1 (en)	2009-08-10	2011-02-17	Robert Bayer	Antibodies with enhanced adcc functions
PT2464725T (pt)	2009-08-11	2020-05-21	Hoffmann La Roche	Produção de proteínas em meios de cultura celular isentos de glutamina
RU2012109556A (ru)	2009-08-14	2013-09-20	Дженентек, Инк.	Биологические маркеры для мониторирования ответа пациента на антагонисты vegf
US20110053223A1 (en)	2009-08-14	2011-03-03	Robert Bayer	Cell culture methods to make antibodies with enhanced adcc function
US9321823B2 (en)	2009-09-02	2016-04-26	Genentech, Inc.	Mutant smoothened and methods of using the same
SG179070A1 (en)	2009-09-11	2012-04-27	Genentech Inc	Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
CN102712696A (zh)	2009-09-16	2012-10-03	弗·哈夫曼-拉罗切有限公司	包含卷曲螺旋和/或系链的蛋白质复合体及其用途
US9200071B2 (en)	2009-09-30	2015-12-01	Genentech, Inc.	Methods of treating cancer using Notch1 and Notch3 antagonists
KR101953075B1 (ko)	2009-10-07	2019-02-27	제넨테크, 인크.	루푸스의 치료, 진단 및 모니터링 방법
WO2011060015A1 (en)	2009-11-11	2011-05-19	Genentech, Inc.	Methods and compositions for detecting target proteins
US9260517B2 (en)	2009-11-17	2016-02-16	Musc Foundation For Research Development	Human monoclonal antibodies to human nucleolin
US11377485B2 (en)	2009-12-02	2022-07-05	Academia Sinica	Methods for modifying human antibodies by glycan engineering
US10087236B2 (en)	2009-12-02	2018-10-02	Academia Sinica	Methods for modifying human antibodies by glycan engineering
TWI505836B (zh)	2009-12-11	2015-11-01	Genentech Inc	抗－ｖｅｇｆ－ｃ抗體及其使用方法
AU2010339770B2 (en)	2009-12-21	2015-02-12	Genentech, Inc.	Antibody formulation
DK2536748T3 (da)	2010-02-18	2014-10-13	Genentech Inc	Neuregulin-antagonister og anvendelse deraf ved behandling af kræft
AR080795A1 (es)	2010-03-24	2012-05-09	Genentech Inc	Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
AR080793A1 (es)	2010-03-26	2012-05-09	Roche Glycart Ag	Anticuerpos biespecificos
WO2011130332A1 (en)	2010-04-12	2011-10-20	Academia Sinica	Glycan arrays for high throughput screening of viruses
EP2975409B1 (en)	2010-05-10	2018-10-31	Academia Sinica	Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
WO2011146568A1 (en)	2010-05-19	2011-11-24	Genentech, Inc.	Predicting response to a her inhibitor
WO2011147834A1 (en)	2010-05-26	2011-12-01	Roche Glycart Ag	Antibodies against cd19 and uses thereof
NZ602840A (en)	2010-06-03	2014-11-28	Genentech Inc	Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
EP2582729A4 (en)	2010-06-18	2014-05-28	Hoffmann La Roche	ANTI-AXL ANTIBODIES AND METHOD FOR THEIR USE
WO2011161119A1 (en)	2010-06-22	2011-12-29	F. Hoffmann-La Roche Ag	Antibodies against insulin-like growth factor i receptor and uses thereof
WO2011161189A1 (en)	2010-06-24	2011-12-29	F. Hoffmann-La Roche Ag	Anti-hepsin antibodies and methods of use
AU2011274528B2 (en)	2010-07-09	2015-04-23	Genentech, Inc.	Anti-neuropilin antibodies and methods of use
CN104634971A (zh)	2010-07-19	2015-05-20	霍夫曼-拉罗奇有限公司	鉴定响应抗癌疗法的可能性升高的患者的方法
EP2848940A1 (en)	2010-07-19	2015-03-18	F. Hoffmann-La Roche AG	Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
WO2012010582A1 (en)	2010-07-21	2012-01-26	Roche Glycart Ag	Anti-cxcr5 antibodies and methods of use
BR112013002535A2 (pt)	2010-08-03	2019-09-24	Hoffmann La Roche	biomarcadores de leucemia linfocítica crônica (cll)
EP2600898A1 (en)	2010-08-05	2013-06-12	F.Hoffmann-La Roche Ag	Anti-mhc antibody anti-viral cytokine fusion protein
US9011847B2 (en)	2010-08-13	2015-04-21	Roche Glycart, AG	Anti-FAP antibodies and methods of use
EP2603529A1 (en)	2010-08-13	2013-06-19	Roche Glycart AG	Anti-tenascin-c a2 antibodies and methods of use
EP2609111B1 (en)	2010-08-24	2017-11-01	F. Hoffmann-La Roche AG	Bispecific antibodies comprising a disulfide stabilized-fv fragment
ES2553262T3 (es)	2010-08-25	2015-12-07	F. Hoffmann-La Roche Ag	Anticuerpos contra la IL-18R1 y usos de los mismos
EP2612151B1 (en)	2010-08-31	2017-08-09	Genentech, Inc.	Biomarkers and methods of treatment
US8481680B2 (en)	2010-10-05	2013-07-09	Genentech, Inc.	Mutant smoothened and methods of using the same
CN103228674B (zh)	2010-11-10	2019-07-05	霍夫曼-拉罗奇有限公司	用于神经疾病免疫疗法的方法和组合物
WO2012083132A2 (en)	2010-12-16	2012-06-21	Genentech, Inc.	Diagnosis and treatments relating to th2 inhibition
BR112013014527A2 (pt)	2010-12-20	2017-03-07	Genentech Inc	anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, uso do imunoconjugado, método para tratamento de um indivíduo que tem um câncer positivo para mesotelina, para inibição de proliferação de uma célula positiva para mesotelina, para detecção de mesotelina humana em uma amostra biológica e para detectar um câncer positivo para mesotelina
AR084456A1 (es)	2010-12-22	2013-05-15	Genentech Inc	Anticuerpo anti-pcsk9 y metodos de uso
EP2655413B1 (en)	2010-12-23	2019-01-16	F.Hoffmann-La Roche Ag	Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
EP2673283B1 (en)	2011-02-09	2017-08-23	Roche Diagnostics GmbH	New iridium-based complexes for ecl
MX342921B (es)	2011-02-09	2016-10-19	Hoffmann La Roche	Nuevos complejos a base de iridio para electroquimioluminiscencia (ecl).
SG192673A1 (en)	2011-02-10	2013-09-30	Roche Glycart Ag	Mutant interleukin-2 polypeptides
MX2013009151A (es)	2011-02-10	2013-08-29	Roche Glycart Ag	Inmunoterapia mejorada.
BR112013019975A2 (pt)	2011-02-28	2017-08-01	Hoffmann La Roche	proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
CN103403025B (zh)	2011-02-28	2016-10-12	弗·哈夫曼-拉罗切有限公司	单价抗原结合蛋白
HUE036229T2 (hu)	2011-03-02	2018-06-28	Roche Glycart Ag	CEA antitestek
DK3556774T3 (da)	2011-03-11	2024-03-25	Univ Emory	Anti-CD40-antistoffer og anvendelser deraf
WO2012123294A1 (en)	2011-03-11	2012-09-20	Roche Diagnostics Gmbh	Apex1 as marker for chronic obstructive pulmonary disease (copd)
ES2578477T3 (es)	2011-03-11	2016-07-27	Roche Diagniostics Gmbh	ASC como marcador de la enfermedad pulmonar obstructiva crónica (EPOC)
CA2826812A1 (en)	2011-03-11	2012-09-20	F. Hoffmann-La Roche Ag	Fen1 as marker for chronic obstructive pulmonary disease (copd)
CA2826818A1 (en)	2011-03-11	2012-09-20	F. Hoffmann-La Roche Ag	Nnmt as marker for chronic obstructive pulmonary disease (copd)
JP5976693B2 (ja)	2011-03-11	2016-08-24	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	慢性閉塞性肺疾患（ｃｏｐｄ）のマーカーとしてのａｒｍｅｔ
WO2012123293A1 (en)	2011-03-11	2012-09-20	Roche Diagnostics Gmbh	Seprase as marker for chronic obstructive pulmonary disease (copd)
EP2689252A1 (en)	2011-03-25	2014-01-29	Roche Diagnostics GmbH	MEASUREMENT OF C-TERMINAL proSP-B
EP2691417B2 (en)	2011-03-29	2024-10-30	Roche Glycart AG	Antibody fc variants
BR112013024717A2 (pt)	2011-04-07	2017-08-08	Genentech Inc	anticorpo isolado, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, método de tratar um indivíduo que tem câncer e método de inibir proliferação celular em um indivíduo
CN103502273A (zh)	2011-04-20	2014-01-08	罗氏格黎卡特股份公司	用于pH依赖性通过血脑屏障的方法和构建体
EA201892619A1 (ru)	2011-04-29	2019-04-30	Роше Гликарт Аг	Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP2707723B1 (en)	2011-05-12	2016-02-10	Genentech, Inc.	Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
MX339662B (es)	2011-05-16	2016-06-03	Genentech Inc	Antagonistas de fgfr1 y sus metodos de uso.
AR086924A1 (es)	2011-06-15	2014-01-29	Hoffmann La Roche	Anticuerpos anti-receptor de epo humano y los metodos para su utilizacion
BR112013030472A2 (pt)	2011-06-30	2019-09-24	Genentech Inc	formulação farmacêutica, artigo de fabricação e método
CN103890007A (zh)	2011-08-17	2014-06-25	霍夫曼-拉罗奇有限公司	神经调节蛋白抗体及其用途
MY171038A (en)	2011-08-23	2019-09-23	Roche Glycart Ag	Bispecific antigen binding molecules
US20130078250A1 (en)	2011-08-23	2013-03-28	Oliver Ast	Bispecific t cell activating antigen binding molecules
US9309306B2 (en)	2011-08-23	2016-04-12	Roche Glycart Ag	Anti-MCSP antibodies
CN103748114B (zh)	2011-08-23	2017-07-21	罗切格利卡特公司	T细胞活化性双特异性抗原结合分子
EP2756300A1 (en)	2011-09-15	2014-07-23	F.Hoffmann-La Roche Ag	Methods of promoting differentiation
US20130078252A1 (en)	2011-09-19	2013-03-28	Genentech, Inc.	Combination treatments comprising c-met antagonists and b-raf antagonists
BR112014008212A2 (pt)	2011-10-05	2017-06-13	Genentech Inc	método para tratar uma condição hepática, método de indução por diferenciação hepática e método de redução de proliferação anormal do ducto biliar
SG11201401477XA (en)	2011-10-14	2014-07-30	Genentech Inc	ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
WO2013056148A2 (en)	2011-10-15	2013-04-18	Genentech, Inc.	Methods of using scd1 antagonists
WO2013059531A1 (en)	2011-10-20	2013-04-25	Genentech, Inc.	Anti-gcgr antibodies and uses thereof
CN103946239A (zh)	2011-10-26	2014-07-23	加利福尼亚大学董事会	用于治疗b细胞慢性淋巴细胞性白血病和其他恶性血液病的cd44单克隆抗体
BR112014009953A2 (pt)	2011-10-28	2017-12-05	Genentech Inc	método de inibição do crescimento de tumores, de tratamento de melanoma, artigo industrializado e uso
KR20140095096A (ko)	2011-11-21	2014-07-31	제넨테크, 인크.	항-c-met 항체의 정제
AR089028A1 (es)	2011-11-29	2014-07-23	Genentech Inc	Composiciones y metodos para el analisis de cancer de prostata
EP2788024A1 (en)	2011-12-06	2014-10-15	F.Hoffmann-La Roche Ag	Antibody formulation
SG10201900915WA (en)	2011-12-22	2019-03-28	Hoffmann La Roche	Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
RU2756106C2 (ru)	2011-12-22	2021-09-28	Ф. Хоффманн-Ля Рош Аг	Строение экспрессионного вектора, новые способы получения клеток-продуцентов и их применение для рекомбинантного получения полипептидов
WO2013096791A1 (en)	2011-12-23	2013-06-27	Genentech, Inc.	Process for making high concentration protein formulations
EP2802601B1 (en)	2012-01-09	2019-11-13	The Scripps Research Institute	Humanized antibodies with ultralong cdr3s
US10774132B2 (en)	2012-01-09	2020-09-15	The Scripps Research Instittue	Ultralong complementarity determining regions and uses thereof
KR20140114415A (ko)	2012-01-13	2014-09-26	제넨테크, 인크.	Vegf 길항제로의 치료를 위한 환자를 확인하기 위한 생물학적 마커
WO2013109856A2 (en)	2012-01-18	2013-07-25	Genentech, Inc.	Methods of using fgf19 modulators
AU2013209707A1 (en)	2012-01-18	2014-07-24	Genentech, Inc.	Anti-LRP5 antibodies and methods of use
WO2013113641A1 (en)	2012-01-31	2013-08-08	Roche Glycart Ag	Use of nkp46 as a predictive biomarker for cancer treatment with adcc- enhanced antibodies
JP6486686B2 (ja)	2012-02-10	2019-03-20	ジェネンテック，インコーポレイテッド	単鎖抗体及び他のヘテロ多量体
JP6545959B2 (ja)	2012-02-11	2019-07-17	ジェネンテック，インコーポレイテッド	Ｒスポンジン転位およびその使用方法
WO2013120929A1 (en)	2012-02-15	2013-08-22	F. Hoffmann-La Roche Ag	Fc-receptor based affinity chromatography
WO2013127465A1 (en)	2012-03-02	2013-09-06	Roche Glycart Ag	Predicitive biomarker for cancer treatment with adcc enhanced antibodies
CA2865082A1 (en)	2012-03-27	2013-10-03	Genentech, Inc.	Diagnosis and treatments relating to her3 inhibitors
AR090549A1 (es)	2012-03-30	2014-11-19	Genentech Inc	Anticuerpos anti-lgr5 e inmunoconjugados
EP2830661A4 (en)	2012-03-30	2016-05-18	Hoffmann La Roche	DIAGNOSTIC METHOD AND COMPOSITIONS FOR CANCER TREATMENT
US10130714B2 (en)	2012-04-14	2018-11-20	Academia Sinica	Enhanced anti-influenza agents conjugated with anti-inflammatory activity
JP6242865B2 (ja)	2012-05-01	2017-12-06	ジェネンテック，インコーポレイテッド	抗ｐｍｅｌ１７抗体および免疫複合体
WO2013170191A1 (en)	2012-05-11	2013-11-14	Genentech, Inc.	Methods of using antagonists of nad biosynthesis from nicotinamide
KR101843614B1 (ko)	2012-05-23	2018-03-29	제넨테크, 인크.	치료제의 선택 방법
MX2014014830A (es)	2012-06-15	2015-05-11	Genentech Inc	Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso.
CA2871882A1 (en)	2012-06-27	2014-01-03	F. Hoffmann-La Roche Ag	Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
KR20150023906A (ko)	2012-06-27	2015-03-05	에프. 호프만-라 로슈 아게	둘 이상의 상이한 표적 독립체를 함유하는 맞춤형의 선별적인 다중특이적 치료용 분자의 선별 및 제조 방법 및 그의 용도
CA2871880A1 (en)	2012-06-27	2014-01-03	F. Hoffmann-La Roche Ag	Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
RU2630664C2 (ru)	2012-07-04	2017-09-11	Ф. Хоффманн-Ля Рош Аг	Антитела к теофиллину и способы их применения
DK2869848T3 (en)	2012-07-04	2016-11-21	Hoffmann La Roche	Covalent BOUND ANTIGEN-ANTIBODY CONJUGATES
KR20150030755A (ko)	2012-07-04	2015-03-20	에프. 호프만-라 로슈 아게	항-바이오틴 항체 및 사용 방법
EP3578660A1 (en)	2012-07-05	2019-12-11	F. Hoffmann-La Roche AG	Expression and secretion system
TR201802376T4 (tr)	2012-07-09	2018-03-21	Genentech Inc	Anti-CD79b antikorları içeren immünokonjugatlar.
US20140030281A1 (en)	2012-07-09	2014-01-30	Genentech, Inc.	Anti-cd22 antibodies and immunoconjugates
MX2015000359A (es)	2012-07-09	2015-04-14	Genentech Inc	Anticuerpos e inmunoconjugados anti-cd79b.
WO2014011518A1 (en)	2012-07-09	2014-01-16	Genentech, Inc.	Immunoconjugates comprising anti-cd22 antibodies
MX361337B (es)	2012-07-13	2018-12-04	Roche Glycart Ag	Anticuerpos biespecificos anti-factor de crecimiento endotelial vascular humano (vegf) / anti-angiopoyetina-2 humana (ang-2) y su uso en el tratamiento de enfermedades vasculares oculares.
CN112587671A (zh)	2012-07-18	2021-04-02	博笛生物科技有限公司	癌症的靶向免疫治疗
WO2014019707A2 (en)	2012-08-02	2014-02-06	Roche Diagnostics Gmbh	New iridium-based complexes for ecl
CN107602620B (zh)	2012-08-02	2020-08-28	霍夫曼-拉罗奇有限公司	用于ecl的新型铱基络合物
WO2014019711A1 (en)	2012-08-02	2014-02-06	Roche Diagnostics Gmbh	New iridium-based complexes for ecl
JP6560120B2 (ja)	2012-08-02	2019-08-14	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Ｅｃｌ製造用の新規ビス−イリジウム錯体
WO2014019709A2 (en)	2012-08-02	2014-02-06	Roche Diagnostics Gmbh	New iridium-based complexes for ecl
BR112014030414A2 (pt)	2012-08-07	2018-05-29	Roche Glycart Ag	combinação de um imunoconjugado, composição farmacêutica, uso de um imunoconjugado, métodos de tratamento e de estímulo, kit e invenção.
PE20150645A1 (es)	2012-08-08	2015-05-11	Roche Glycart Ag	Proteinas de fusion de interleuquina 10 y usos de las mismas
US9771427B2 (en)	2012-08-09	2017-09-26	Roche Glycart Ag	ASGPR antibodies and uses thereof
CA2880701A1 (en)	2012-08-18	2014-02-27	Academia Sinica	Cell-permeable probes for identification and imaging of sialidases
EP2888238A4 (en)	2012-08-21	2016-01-27	Academia Sinica	BENZOCYCLOOCTYN COMPOUNDS AND USES THEREOF
WO2014071358A2 (en)	2012-11-05	2014-05-08	Foundation Medicine, Inc.	Novel ntrk1 fusion molecules and uses thereof
AU2013343667A1 (en)	2012-11-08	2015-04-02	F. Hoffmann-La Roche Ag	HER3 antigen binding proteins binding to the beta-hairpin of HER3
TWI657095B (zh)	2012-11-13	2019-04-21	美商建南德克公司	抗血球凝集素抗體及使用方法
AU2013204922B2 (en)	2012-12-20	2015-05-14	Celgene Corporation	Chimeric antigen receptors
US10980804B2 (en)	2013-01-18	2021-04-20	Foundation Medicine, Inc.	Methods of treating cholangiocarcinoma
WO2014116749A1 (en)	2013-01-23	2014-07-31	Genentech, Inc.	Anti-hcv antibodies and methods of using thereof
WO2014114595A1 (en)	2013-01-23	2014-07-31	Roche Glycart Ag	Predictive biomarker for cancer treatment with adcc-enhanced antibodies
CA2900097A1 (en)	2013-02-22	2014-08-28	F. Hoffmann-La Roche Ag	Methods of treating cancer and preventing drug resistance
US20140242083A1 (en)	2013-02-26	2014-08-28	Roche Glycart Ag	Anti-mcsp antibodies
CN104936985A (zh)	2013-02-26	2015-09-23	罗切格利卡特公司	双特异性t细胞活化性抗原结合分子
CA2896370A1 (en)	2013-02-26	2014-09-04	Roche Glycart Ag	Bispecific t cell activating antigen binding molecules
EA031214B1 (ru)	2013-02-26	2018-12-28	Роше Гликарт Аг	Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
JP2016510751A (ja)	2013-03-06	2016-04-11	ジェネンテック，インコーポレイテッド	抗がん剤耐性を治療及び予防する方法
RS60534B1 (sr)	2013-03-13	2020-08-31	Hoffmann La Roche	Formulacije sa smanjenom oksidacijom
EP2968466B1 (en)	2013-03-13	2018-07-25	F.Hoffmann-La Roche Ag	Formulations with reduced oxidation
AR095399A1 (es)	2013-03-13	2015-10-14	Genentech Inc	Formulaciones con oxidación reducida, método
US20140314778A1 (en)	2013-03-13	2014-10-23	Genentech, Inc.	Formulations with reduced oxidation
SG11201507475UA (en)	2013-03-13	2015-10-29	Genentech Inc	Antibody formulations
WO2014153030A2 (en)	2013-03-14	2014-09-25	Genentech, Inc.	Methods of treating cancer and preventing cancer drug resistance
CN105246508A (zh)	2013-03-14	2016-01-13	基因泰克公司	Mek抑制剂化合物与her3/egfr抑制剂化合物的组合及使用方法
WO2014159835A1 (en)	2013-03-14	2014-10-02	Genentech, Inc.	Anti-b7-h4 antibodies and immunoconjugates
CN105143265A (zh)	2013-03-15	2015-12-09	豪夫迈·罗氏有限公司	抗CRTh2抗体及其用途
EP2968537A1 (en)	2013-03-15	2016-01-20	Genentech, Inc.	Methods of treating cancer and preventing cancer drug resistance
SG11201507333XA (en)	2013-03-15	2015-10-29	Genentech Inc	Biomarkers and methods of treating pd-1 and pd-l1 related conditions
KR102233349B1 (ko)	2013-03-15	2021-03-31	에이씨 이뮨 에스.에이.	항-타우(tau) 항체 및 사용 방법
CN105283196B (zh)	2013-03-15	2018-10-12	贝丝以色列女执事医疗中心	用于产生和使用构象-特异性抗体的方法和组合物
BR112015020290A2 (pt)	2013-03-15	2017-10-10	Genentech Inc	métodos para tratar um câncer, para prevenir câncer, para inibir proliferação, para tratar terapeuticamente um mamífero, para tratar uma disfunção, para reduzir níveis de proteína spp1, para tratar terapeuticamente um câncer, para tratar um indivíduo e para inibir proliferação celular, artigo, anticorpos e usos
EP2968544A4 (en)	2013-03-15	2016-10-12	Hoffmann La Roche	CELL CULTURE MEDIA AND METHOD FOR PRODUCING ANTIBODY
CN105518018B (zh)	2013-03-15	2020-04-03	细胞基因公司	修饰的t淋巴细胞
SG11201509566RA (en)	2013-05-20	2015-12-30	Genentech Inc	Anti-transferrin receptor antibodies and methods of use
US10086054B2 (en)	2013-06-26	2018-10-02	Academia Sinica	RM2 antigens and use thereof
EP3013347B1 (en)	2013-06-27	2019-12-11	Academia Sinica	Glycan conjugates and use thereof
AU2014290361B2 (en)	2013-07-18	2019-04-18	Taurus Biosciences, Llc	Humanized antibodies with ultralong complementarity determining regions
US20160168231A1 (en)	2013-07-18	2016-06-16	Fabrus, Inc.	Antibodies with ultralong complementarity determining regions
US10456470B2 (en)	2013-08-30	2019-10-29	Genentech, Inc.	Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en)	2013-08-30	2020-04-14	Genentech, Inc.	Combination therapy for the treatment of glioblastoma
CN105682666B (zh)	2013-09-06	2021-06-01	中央研究院	使用醣脂激活人类iNKT细胞
JP2016537399A (ja)	2013-09-17	2016-12-01	ジェネンテック，インコーポレイテッド	抗ｌｇｒ５抗体を使用する方法
JP6431920B2 (ja)	2013-09-17	2018-11-28	オービーアイファーマ，インコーポレイテッド	免疫反応を誘導する炭水化物ワクチンの組成とがんの治療におけるその使用
AR097791A1 (es)	2013-09-27	2016-04-13	Genentech Inc	Formulaciones de anticuerpos anti-pdl1
US10414818B2 (en)	2013-09-27	2019-09-17	Roche Diagnostics Operations, Inc.	Thermus thermophilus SlyD FKBP domain specific antibodies
JP6422956B2 (ja)	2013-10-11	2018-11-14	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	多重特異性ドメイン交換共通可変軽鎖抗体
CA2926084A1 (en)	2013-10-11	2015-04-16	Genentech, Inc.	Nsp4 inhibitors and methods of use
BR112016008477A2 (pt)	2013-10-18	2017-10-03	Genentech Inc	Corpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo
BR112016008694A2 (pt)	2013-10-23	2017-10-03	Genentech Inc	Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit
CN111499742B (zh)	2013-11-21	2024-05-07	豪夫迈·罗氏有限公司	抗-α-突触核蛋白抗体及使用方法
EA201691214A1 (ru)	2013-12-13	2016-12-30	Дженентек, Инк.	Антитела к cd33 и иммуноконъюгаты
RS59659B2 (sr)	2013-12-17	2023-08-31	Hoffmann La Roche	Postupci lečenjа raka pomoću аntаgonistа koji vežu osovinu pd-1 i pomoću tаksаnа
MX2016007965A (es)	2013-12-17	2016-10-28	Genentech Inc	Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1.
KR102225489B1 (ko)	2013-12-17	2021-03-10	제넨테크, 인크.	항-cd3 항체 및 이의 사용 방법
LT3083680T (lt)	2013-12-20	2020-04-10	F. Hoffmann-La Roche Ag	Humanizuoti anti-tau(ps422) antikūnai ir jų naudojimo būdai
TWI670283B (zh)	2013-12-23	2019-09-01	美商建南德克公司	抗體及使用方法
CA2930154A1 (en)	2014-01-03	2015-07-09	F. Hoffmann-La Roche Ag	Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
WO2015101589A1 (en)	2014-01-03	2015-07-09	F. Hoffmann-La Roche Ag	Covalently linked polypeptide toxin-antibody conjugates
PL3089996T3 (pl)	2014-01-03	2021-12-13	F. Hoffmann-La Roche Ag	Dwuswoiste przeciwciała przeciw haptenowi/przeciw receptorowi występującemu w barierze krew-mózg, ich kompleksy i ich zastosowanie jako przenośniki wahadłowe występujące w barierze krew-mózg
CN111057147B (zh)	2014-01-06	2023-11-10	豪夫迈·罗氏有限公司	单价血脑屏障穿梭模块
AU2015205753A1 (en)	2014-01-10	2016-07-21	Birdie Biopharmaceuticals Inc.	Compounds and compositions for treating HER2 positive tumors
WO2016114819A1 (en)	2015-01-16	2016-07-21	Academia Sinica	Compositions and methods for treatment and detection of cancers
WO2015109180A2 (en)	2014-01-16	2015-07-23	Academia Sinica	Compositions and methods for treatment and detection of cancers
US10150818B2 (en)	2014-01-16	2018-12-11	Academia Sinica	Compositions and methods for treatment and detection of cancers
SG11201605903SA (en)	2014-01-24	2016-08-30	Genentech Inc	Methods of using anti-steap1 antibodies and immunoconjugates
WO2015120075A2 (en)	2014-02-04	2015-08-13	Genentech, Inc.	Mutant smoothened and methods of using the same
SG11201606490YA (en)	2014-02-08	2016-09-29	Genentech Inc	Methods of treating alzheimer's disease
BR112016018170A2 (pt)	2014-02-08	2018-02-20	Genentech, Inc.	métodos para tratar doença de alzheimer
TW201902515A (zh)	2014-02-12	2019-01-16	美商建南德克公司	抗jagged1抗體及使用方法
BR112016018980A2 (pt)	2014-02-21	2017-10-10	Genentech Inc	método de tratamento de um distúrbio, anticorpo multiespecífico, ácido nucleico isolado, célula hospedeira, métodos de produzir um anticorpo, de produção de uma metade de anticorpo ou de um anticorpo multiespecífico e de produção de um anticorpo multiespecífico, imunoconjugado e formulação farmacêutica
HRP20211748T1 (hr)	2014-03-14	2022-02-18	F. Hoffmann - La Roche Ag	Postupci i sastavi za sekreciju heterolognih polipeptida
US20170107294A1 (en)	2014-03-21	2017-04-20	Nordlandssykehuset Hf	Anti-cd14 antibodies and uses thereof
CN107002119A (zh)	2014-03-24	2017-08-01	豪夫迈·罗氏有限公司	使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
TWI797430B (zh)	2014-03-27	2023-04-01	中央研究院	反應性標記化合物及其用途
SG11201607969XA (en)	2014-03-31	2016-10-28	Genentech Inc	Anti-ox40 antibodies and methods of use
JP6588461B2 (ja)	2014-03-31	2019-10-09	ジェネンテック，インコーポレイテッド	抗血管新生剤及びｏｘ４０結合アゴニストを含む併用療法
ES2845650T3 (es)	2014-04-18	2021-07-27	Acceleron Pharma Inc	Procedimientos para aumentar los niveles de glóbulos rojos y tratar la drepanocitosis
WO2015164615A1 (en)	2014-04-24	2015-10-29	University Of Oslo	Anti-gluten antibodies and uses thereof
MX370018B (es)	2014-04-25	2019-11-28	Bluebird Bio Inc	Metodos mejorados para la elaboracion de terapias celulares adoptivas.
MX2016013964A (es)	2014-04-25	2017-04-06	Bluebird Bio Inc	Receptores de antigenos quimericos del promotor mnd.
DK3140653T3 (da)	2014-05-08	2022-06-20	Novodiax Inc	Direkte immunhistokemianalyse
RU2016150370A (ru)	2014-05-22	2018-06-26	Дженентек, Инк.	Антитела и иммуноконъюгаты против GPC3
EP3146071B1 (en)	2014-05-23	2020-09-02	F. Hoffmann-La Roche AG	Mit biomarkers and methods using the same
TWI654202B (zh)	2014-05-27	2019-03-21	中央研究院	增進抗體功效之通用糖型之組合物及方法
US10118969B2 (en)	2014-05-27	2018-11-06	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
WO2015184004A1 (en)	2014-05-27	2015-12-03	Academia Sinica	Anti-cd20 glycoantibodies and uses thereof
CN106661099A (zh)	2014-05-27	2017-05-10	中央研究院	抗her2醣抗体及其用途
EP3154582A4 (en)	2014-05-28	2018-01-10	Academia Sinica	Anti-tnf-alpha glycoantibodies and uses thereof
SMT202100049T1 (it)	2014-06-06	2021-03-15	Bluebird Bio Inc	Composizioni di cellule t migliorate
JP2017526618A (ja)	2014-06-11	2017-09-14	ジェネンテック，インコーポレイテッド	抗ＬｇＲ５抗体及びその使用
CN107135646B (zh)	2014-06-13	2022-03-15	阿塞勒隆制药公司	用于治疗溃疡的方法和组合物
WO2015191986A1 (en)	2014-06-13	2015-12-17	Genentech, Inc.	Methods of treating and preventing cancer drug resistance
AR100978A1 (es)	2014-06-26	2016-11-16	Hoffmann La Roche	LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
BR112016029935A2 (pt)	2014-06-26	2017-10-31	Hoffmann La Roche	?anticorpos anti-brdu, complexo, formulação farmacêutica e uso de anticorpo?
EP3680336A1 (en)	2014-07-03	2020-07-15	F. Hoffmann-La Roche AG	Polypeptide expression systems
CN112546230A (zh)	2014-07-09	2021-03-26	博笛生物科技有限公司	用于治疗癌症的联合治疗组合物和联合治疗方法
TWI727427B (zh)	2014-07-09	2021-05-11	英屬開曼群島商博笛生物科技有限公司	用於治療腫瘤的抗pd-1組合
RU2017103289A (ru)	2014-07-11	2018-08-14	Дженентек, Инк.	Ингибирование пути notch
CN106604933B (zh)	2014-07-11	2021-08-10	文塔纳医疗系统公司	抗pd-l1抗体及其诊断用途
EP3169801A1 (en)	2014-07-14	2017-05-24	F. Hoffmann-La Roche AG	Diagnostic methods and compositions for treatment of glioblastoma
AU2015292590B2 (en)	2014-07-24	2020-01-16	2Seventy Bio, Inc.	BCMA chimeric antigen receptors
FI3177643T5 (fi)	2014-08-04	2023-11-28	Hoffmann La Roche	T-soluja aktivoivia bispesifisiä antigeeniä sitovia molekyylejä
WO2016033331A1 (en)	2014-08-28	2016-03-03	Bioatla, Llc	Conditionally active chimeric antigen receptors for modified t-cells
CN112587672A (zh)	2014-09-01	2021-04-02	博笛生物科技有限公司	用于治疗肿瘤的抗-pd-l1结合物
TWI745275B (zh)	2014-09-08	2021-11-11	中央研究院	使用醣脂激活人類ｉＮＫＴ細胞
TW201625689A (zh)	2014-09-12	2016-07-16	建南德克公司	抗－ｂ７－ｈ４抗體及免疫結合物
SI3191135T1 (sl)	2014-09-12	2021-01-29	Genentech, Inc.	Anti-HER2 protitelesa in imunokonjugati
SG10201804931QA (en)	2014-09-12	2018-07-30	Genentech Inc	Anti-cll-1 antibodies and immunoconjugates
RU2704611C2 (ru)	2014-09-15	2019-10-30	Дженентек, Инк.	Составы на основе антител
KR20170055521A (ko)	2014-09-17	2017-05-19	제넨테크, 인크.	항-her2 항체를 포함하는 면역콘주게이트
CA3069221C (en)	2014-09-23	2023-04-04	Genentech, Inc.	Methods of using anti-cd79b immunoconjugates
US10233232B2 (en)	2014-10-14	2019-03-19	Deutsches Krebsforschungszentrum	Norovirus antibodies
CN107074938A (zh)	2014-10-16	2017-08-18	豪夫迈·罗氏有限公司	抗‑α‑突触核蛋白抗体和使用方法
AU2015343339A1 (en)	2014-11-03	2017-06-15	Genentech, Inc.	Methods and biomarkers for predicting efficacy and evaluation of an OX40 agonist treatment
CA2966523A1 (en)	2014-11-03	2016-05-12	Genentech, Inc.	Assays for detecting t cell immune subsets and methods of use thereof
WO2016073794A1 (en)	2014-11-05	2016-05-12	Genentech, Inc.	Methods of producing two chain proteins in bacteria
RU2705274C2 (ru)	2014-11-05	2019-11-06	Дженентек, Инк.	Способы получения двуцепочечных белков в бактериях
AU2015343494A1 (en)	2014-11-06	2017-04-27	Genentech, Inc.	Combination therapy comprising OX40 binding agonists and TIGIT inhibitors
WO2016073157A1 (en)	2014-11-06	2016-05-12	Genentech, Inc.	Anti-ang2 antibodies and methods of use thereof
JP2018500882A (ja)	2014-11-10	2018-01-18	ジェネンテック，インコーポレイテッド	腎症の動物モデルおよびそれを治療するための薬剤
US10093730B2 (en)	2014-11-10	2018-10-09	Genentech, Inc.	Anti-interleukin-33 antibodies and uses thereof
SI3224275T1 (sl)	2014-11-14	2020-07-31	F. Hoffmann-La Roche Ag	Molekule, ki vežejo antigen in vsebujejo trimer ligandov iz družine TNF
BR112017010198A2 (pt)	2014-11-17	2017-12-26	Genentech Inc	terapia de combinação compreendendo agonistas de ligação a ox40 e antagonistas de ligação ao eixo de pd-1
CN107001473B (zh)	2014-11-19	2021-07-09	豪夫迈·罗氏有限公司	抗-运铁蛋白受体抗体及使用方法
CN107108745B (zh)	2014-11-19	2021-01-12	基因泰克公司	抗bace1的抗体和其用于神经疾病免疫疗法的用途
JP6993228B2 (ja)	2014-11-19	2022-03-03	ジェネンテック，インコーポレイテッド	抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
DK3221357T3 (da)	2014-11-20	2020-08-10	Hoffmann La Roche	Fælles letkæder og fremgangsmåder til anvendelse
RU2753902C2 (ru)	2014-11-20	2021-08-24	Ф.Хоффманн-Ля Рош Аг	Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1
WO2021173560A1 (en)	2020-02-24	2021-09-02	Immatics US, Inc.	Methods for expanding t cells for the treatment of cancer and related malignancies
WO2016087416A1 (en)	2014-12-03	2016-06-09	F. Hoffmann-La Roche Ag	Multispecific antibodies
MA41119A (fr)	2014-12-03	2017-10-10	Acceleron Pharma Inc	Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
WO2016090210A1 (en)	2014-12-05	2016-06-09	Genentech, Inc.	ANTI-CD79b ANTIBODIES AND METHODS OF USE
CA2966365A1 (en)	2014-12-10	2016-06-16	Genentech, Inc.	Blood brain barrier receptor antibodies and methods of use
HRP20211648T1 (hr)	2014-12-12	2022-02-04	2Seventy Bio, Inc.	Kimerni receptori antigena bcma
EP3234601B1 (en)	2014-12-18	2019-10-09	Roche Diagnostics GmbH	Methods for reducing interferences
KR102650420B1 (ko)	2014-12-19	2024-03-21	추가이 세이야쿠 가부시키가이샤	항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
CA2967554A1 (en)	2014-12-19	2016-06-23	Yoshinao Ruike	Anti-c5 antibodies and methods of use
US9975965B2 (en)	2015-01-16	2018-05-22	Academia Sinica	Compositions and methods for treatment and detection of cancers
US10495645B2 (en)	2015-01-16	2019-12-03	Academia Sinica	Cancer markers and methods of use thereof
WO2016117346A1 (en)	2015-01-22	2016-07-28	Chugai Seiyaku Kabushiki Kaisha	A combination of two or more anti-c5 antibodies and methods of use
EP3789766A1 (en)	2015-01-24	2021-03-10	Academia Sinica	Novel glycan conjugates and methods of use thereof
KR102620346B1 (ko)	2015-01-30	2024-01-02	아카데미아 시니카	증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법
WO2016126972A1 (en)	2015-02-04	2016-08-11	Genentech, Inc.	Mutant smoothened and methods of using the same
TW202248212A (zh)	2015-02-05	2022-12-16	日商中外製藥股份有限公司	包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途
US20170151281A1 (en)	2015-02-19	2017-06-01	Batu Biologics, Inc.	Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
AU2016233398A1 (en)	2015-03-16	2017-09-07	F. Hoffmann-La Roche Ag	Methods of detecting and quantifying IL-13 and uses in diagnosing and treating Th2-associated diseases
WO2016146833A1 (en)	2015-03-19	2016-09-22	F. Hoffmann-La Roche Ag	Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
MA41919A (fr)	2015-04-06	2018-02-13	Acceleron Pharma Inc	Hétéromultimères alk4:actriib et leurs utilisations
US10227393B2 (en)	2015-04-06	2019-03-12	Acceleron Pharma Inc.	TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof
CN107708733B (zh)	2015-04-07	2022-11-15	艾利妥	抗分拣蛋白抗体和其使用方法
AU2016246695A1 (en)	2015-04-07	2017-10-26	Genentech, Inc.	Antigen binding complex having agonistic activity and methods of use
CN108064343B (zh)	2015-04-21	2021-07-09	基因泰克公司	用于前列腺癌分析的组合物和方法
EP3913052A1 (en)	2015-04-24	2021-11-24	F. Hoffmann-La Roche AG	Methods of identifying bacteria comprising binding polypeptides
EP3778640A1 (en)	2015-05-01	2021-02-17	Genentech, Inc.	Masked anti-cd3 antibodies and methods of use
WO2016183104A1 (en)	2015-05-11	2016-11-17	Genentech, Inc.	Compositions and methods of treating lupus nephritis
IL295002A (en)	2015-05-12	2022-09-01	Genentech Inc	Therapeutic and diagnostic methods for cancer comprising a pd-l1 binding antagonist
JP2018520658A (ja)	2015-05-29	2018-08-02	ジェネンテック，インコーポレイテッド	ヒト化抗エボラウイルス糖タンパク質抗体及びその使用
ES2789500T5 (es)	2015-05-29	2023-09-20	Hoffmann La Roche	Procedimientos terapéuticos y de diagnóstico para el cáncer
KR20180011117A (ko)	2015-05-31	2018-01-31	큐어제닉스 코포레이션	면역 요법용 복합 조성물
WO2016196679A1 (en)	2015-06-02	2016-12-08	Genentech, Inc.	Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
RU2732122C2 (ru)	2015-06-05	2020-09-11	Дженентек, Инк.	Антитела против тау-белка и способы их применения
AU2016274585A1 (en)	2015-06-08	2017-12-14	Genentech, Inc.	Methods of treating cancer using anti-OX40 antibodies
CA2988420A1 (en)	2015-06-08	2016-12-15	Genentech, Inc.	Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
KR20180033502A (ko)	2015-06-12	2018-04-03	알렉터 엘엘씨	항-cd33 항체 및 그의 사용 방법
EP3307779A2 (en)	2015-06-12	2018-04-18	Alector LLC	Anti-cd33 antibodies and methods of use thereof
CN108064246A (zh)	2015-06-15	2018-05-22	基因泰克公司	抗体和免疫结合物
CN107847568B (zh)	2015-06-16	2022-12-20	豪夫迈·罗氏有限公司	抗cll-1抗体和使用方法
EP3916018A1 (en)	2015-06-16	2021-12-01	Genentech, Inc.	Anti-cd3 antibodies and methods of use
MY189840A (en)	2015-06-16	2022-03-11	Genentech Inc	Humanized and affinity matured antibodies to fcrh5 and methods of use
CA2986263A1 (en)	2015-06-17	2016-12-22	Genentech, Inc.	Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
KR20180012859A (ko)	2015-06-17	2018-02-06	제넨테크, 인크.	항-her2 항체 및 이용 방법
AR105089A1 (es)	2015-06-24	2017-09-06	Hoffmann La Roche	ANTICUERPOS ANTI-TAU(pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
EP3313885A1 (en)	2015-06-29	2018-05-02	H. Hoffnabb-La Roche Ag	Type ii anti-cd20 antibody for use in organ transplantation
EP3514174B1 (en)	2015-06-29	2021-03-31	Ventana Medical Systems, Inc.	Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
EP3331550B1 (en)	2015-08-04	2022-11-02	Acceleron Pharma Inc.	Composition for treating myeloproliferative disorders
CN105384825B (zh)	2015-08-11	2018-06-01	南京传奇生物科技有限公司	一种基于单域抗体的双特异性嵌合抗原受体及其应用
EP3130922A1 (en)	2015-08-11	2017-02-15	Roche Diagnostics GmbH	Alkaline pretreatment of parvoviruses for immunoassays
TR201909273T4 (tr)	2015-08-20	2019-07-22	Hoffmann La Roche	Bir pegile analit spesifik bağlanma ajanının kullanıldığı partikül bazlı immünolojik test.
JP6920786B2 (ja)	2015-08-26	2021-08-18	ドイチェスクレブスフォルシュンクスツェントルム	免疫ウイルス療法のためのｒｎａウイルス
EP3932953A1 (en)	2015-08-28	2022-01-05	F. Hoffmann-La Roche AG	Anti-hypusine antibodies and uses thereof
JP6980659B2 (ja)	2015-08-31	2021-12-15	ヘリックスミスカンパニー，リミテッド	抗シアリルｔｎキメラ抗原受容体
AR105910A1 (es)	2015-09-04	2017-11-22	Obi Pharma Inc	Matrices de glicano y método de uso
BR112018004296B1 (pt)	2015-09-04	2020-05-05	Primatope Therapeutics Inc	anticorpos anti-cd40 humanizados e usos dos mesmos
KR20230079500A (ko)	2015-09-18	2023-06-07	추가이 세이야쿠 가부시키가이샤	Il-8에 결합하는 항체 및 그의 사용
JP6904947B2 (ja)	2015-09-22	2021-07-21	スプリングバイオサイエンスコーポレーション	抗ｏｘ４０抗体及びその診断用途
MY191756A (en)	2015-09-23	2022-07-14	Genentech Inc	Optimized variants of anti-vegf antibodies
BR112018005931A2 (pt)	2015-09-24	2018-10-09	Abvitro Llc	composições de anticorpo para hiv e métodos de uso
EP4360646A3 (en)	2015-09-25	2024-05-15	F. Hoffmann-La Roche AG	Anti-tigit antibodies and methods of use
AR106188A1 (es)	2015-10-01	2017-12-20	Hoffmann La Roche	Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CN115594765A (zh)	2015-10-02	2023-01-13	豪夫迈·罗氏有限公司（Ch）	对共刺激性tnf受体特异性的双特异性抗体
WO2017055392A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
WO2017055385A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
WO2017055393A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
PT3356404T (pt)	2015-10-02	2021-10-14	Hoffmann La Roche	Anticorpos anti-pd1 e métodos de utilização
MA43345A (fr)	2015-10-02	2018-08-08	Hoffmann La Roche	Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
EP3356409A2 (en)	2015-10-02	2018-08-08	H. Hoffnabb-La Roche Ag	Bispecific t cell activating antigen binding molecules
CR20180161A (es)	2015-10-02	2018-05-25	Hoffmann La Roche	Anticuerpos biespecíficos para pd1 y tim3
WO2017055389A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
US20170096485A1 (en)	2015-10-02	2017-04-06	Hoffmann-La Roche Inc.	Bispecific t cell activating antigen binding molecules
US20180282410A1 (en)	2015-10-02	2018-10-04	Hoffmann-La Roche Inc.	Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
WO2017055314A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
US20170247467A1 (en)	2015-10-07	2017-08-31	Hoffmann-La Roche Inc.	Bispecific antibodies with tetravalency for a costimulatory tnf receptor
MA43354A (fr)	2015-10-16	2018-08-22	Genentech Inc	Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr)	2015-10-20	2018-08-29	Genentech Inc	Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
ES2923755T3 (es)	2015-10-23	2022-09-30	Fred Hutchinson Cancer Center	Procedimientos para crear sistemas de proteínas de dimerización inducidos químicamente para la regulación de eventos celulares
EP3184547A1 (en)	2015-10-29	2017-06-28	F. Hoffmann-La Roche AG	Anti-tpbg antibodies and methods of use
BR112018006562A2 (pt)	2015-10-29	2018-12-11	Hoffmann La Roche	anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, conjugado e uso de um anticorpo
UA123773C2 (uk)	2015-10-30	2021-06-02	Дженентек, Інк.	ВИДІЛЕНЕ АНТИТІЛО ПРОТИ HtrA1 ТА ЙОГО ЗАСТОСУВАННЯ ПРИ ЛІКУВАННІ ПОВ'ЯЗАНОГО З HtrA1 ПОРУШЕННЯ АБО ХВОРОБИ ОКА
JP2018534930A (ja)	2015-10-30	2018-11-29	ジェネンテック，インコーポレイテッド	抗ｄ因子抗体及びコンジュゲート
EP3370754A4 (en)	2015-11-04	2019-10-23	Acceleron Pharma Inc.	METHODS FOR INCREASING ERYTHROCYTE RATES AND TREATING INEFFECTIVE ERYTHROPOISIS
CN118725134A (zh)	2015-11-08	2024-10-01	豪夫迈·罗氏有限公司	筛选多特异性抗体的方法
US10550170B2 (en)	2015-11-23	2020-02-04	Acceleron Pharma Inc.	Methods for treating vascular eye disorders with actrii antagonists
US11479755B2 (en)	2015-12-07	2022-10-25	2Seventy Bio, Inc.	T cell compositions
AU2016368469B2 (en)	2015-12-09	2023-11-02	F. Hoffmann-La Roche Ag	Type II anti-CD20 antibody for reducing formation of anti-drug antibodies
EP3178848A1 (en)	2015-12-09	2017-06-14	F. Hoffmann-La Roche AG	Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
PL3390442T3 (pl)	2015-12-18	2024-03-18	Chugai Seiyaku Kabushiki Kaisha	Przeciwciała anty-c5 i sposoby ich stosowania
CA3007419A1 (en)	2015-12-30	2017-07-06	Genentech, Inc.	Formulations with reduced degradation of polysorbate
CA3007491A1 (en)	2015-12-30	2017-07-06	Genentech, Inc.	Use of tryptophan derivatives for protein formulations
MX2018008347A (es)	2016-01-08	2018-12-06	Hoffmann La Roche	Metodos de tratamiento de canceres positivos para ace utilizando antagonistas de union a eje pd-1 y anticuerpos biespecificos anti-ace/anti-cd3.
EP3405489A1 (en)	2016-01-20	2018-11-28	Genentech, Inc.	High dose treatments for alzheimer's disease
US10344067B2 (en)	2016-02-25	2019-07-09	Deutsches Krebsforschungszentrum	RNA viruses expressing IL-12 for immunovirotherapy
US10982136B2 (en)	2016-02-26	2021-04-20	The Regents Of The University Of California	Ligand-sensitized lanthanide nanocrystals as ultraviolet downconverters
EP3423596B1 (en)	2016-02-29	2022-09-28	Genentech, Inc.	Therapeutic and diagnostic methods for cancer
WO2017156032A1 (en)	2016-03-07	2017-09-14	Charlestonpharma, Llc	Anti-nucleolin antibodies
US10336784B2 (en)	2016-03-08	2019-07-02	Academia Sinica	Methods for modular synthesis of N-glycans and arrays thereof
JP6430025B2 (ja)	2016-03-15	2018-11-28	中外製薬株式会社	Ｐｄ−１系結合アンタゴニストおよび抗ｇｐｃ３抗体を使用して癌を治療する方法
CA3012422A1 (en)	2016-03-22	2017-09-28	F. Hoffmann-La Roche Ag	Protease-activated t cell bispecific molecules
US20170315132A1 (en)	2016-03-25	2017-11-02	Genentech, Inc.	Multiplexed total antibody and antibody-conjugated drug quantification assay
EP3231813A1 (en)	2016-03-29	2017-10-18	F. Hoffmann-La Roche AG	Trimeric costimulatory tnf family ligand-containing antigen binding molecules
US10980894B2 (en)	2016-03-29	2021-04-20	Obi Pharma, Inc.	Antibodies, pharmaceutical compositions and methods
EP3436482A4 (en)	2016-03-29	2020-03-11	OBI Pharma, Inc.	ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
EP3865511A1 (en)	2016-04-14	2021-08-18	F. Hoffmann-La Roche AG	Anti-rspo3 antibodies and methods of use
EP3443002A4 (en)	2016-04-14	2019-12-04	Bluebird Bio, Inc.	SYSTEMS FOR RECOVERED CHIMERIC ANTIGEN RECEPTORS
KR20190003957A (ko)	2016-04-15	2019-01-10	제넨테크, 인크.	암 모니터링 및 치료 방법
ES2850428T3 (es)	2016-04-15	2021-08-30	Hoffmann La Roche	Procedimientos de monitorización y tratamiento del cáncer
SG11201808994YA (en)	2016-04-15	2018-11-29	Bioatla Llc	Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
SG11201809024UA (en)	2016-04-22	2018-11-29	Obi Pharma Inc	Cancer immunotherapy by immune activation or immune modulation via globo series antigens
EP3455254B1 (en)	2016-05-11	2021-07-07	F. Hoffmann-La Roche AG	Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
EP3455252B1 (en)	2016-05-11	2022-02-23	F. Hoffmann-La Roche AG	Modified anti-tenascin antibodies and methods of use
EP3243836A1 (en)	2016-05-11	2017-11-15	F. Hoffmann-La Roche AG	C-terminally fused tnf family ligand trimer-containing antigen binding molecules
EP3243832A1 (en)	2016-05-13	2017-11-15	F. Hoffmann-La Roche AG	Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
IL308504A (en)	2016-05-13	2024-01-01	Bioatla Llc	Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
CN109152843A (zh)	2016-05-20	2019-01-04	豪夫迈·罗氏有限公司	Protac抗体缀合物及其使用方法
CN109313200B (zh)	2016-05-27	2022-10-04	豪夫迈·罗氏有限公司	用于表征位点特异性抗体-药物缀合物的生物分析性方法
KR102156994B1 (ko)	2016-05-31	2020-09-17	에프. 호프만-라 로슈 아게	Hcv 코어 항원의 신속한 검출을 위한 전처리 방법
KR102165623B1 (ko)	2016-05-31	2020-10-15	에프. 호프만-라 로슈 아게	바이러스 항원의 혈청학적 탐지 방법
TW201902512A (zh)	2016-06-02	2019-01-16	瑞士商赫孚孟拉羅股份公司	治療方法
EP3252078A1 (en)	2016-06-02	2017-12-06	F. Hoffmann-La Roche AG	Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
EP3464280B1 (en)	2016-06-06	2021-10-06	F. Hoffmann-La Roche AG	Silvestrol antibody-drug conjugates and methods of use
EP3472624B1 (en)	2016-06-15	2020-11-04	Roche Diagnostics GmbH	Improved d-dimer assay calibration
SG11201705585QA (en)	2016-06-17	2018-05-30	Chugai Pharmaceutical Co Ltd	Anti-myostatin antibodies and methods of use
CN116143918A (zh)	2016-06-24	2023-05-23	豪夫迈·罗氏有限公司	抗聚泛素多特异性抗体
CA3030841A1 (en)	2016-07-14	2018-01-18	Fred Hutchinson Cancer Research Center	Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
SI3496739T1 (sl)	2016-07-15	2021-06-30	Acceleron Pharma Inc.	Sestave, ki zajemajo polipeptide actriia, za uporabo pri zdravljenju pljučne hipertenzije
WO2018014260A1 (en)	2016-07-20	2018-01-25	Nanjing Legend Biotech Co., Ltd.	Multispecific antigen binding proteins and methods of use thereof
EP3490592A4 (en)	2016-07-27	2020-03-25	OBI Pharma, Inc.	IMMUNOGENIC / THERAPEUTIC GLYCAN COMPOSITIONS AND USES THEREOF
JP7264580B2 (ja)	2016-07-27	2023-04-25	アクセルロンファーマインコーポレイテッド	骨髄線維症を処置するための方法および組成物
CN117986372A (zh)	2016-07-29	2024-05-07	中外制药株式会社	显示增加的备选fviii辅因子功能活性的双特异性抗体
CN110062767B (zh)	2016-07-29	2023-07-11	台湾浩鼎生技股份有限公司	人抗体、药物组合物和方法
CN109689099B (zh)	2016-08-05	2023-02-28	中外制药株式会社	用于预防或治疗il-8相关疾病的组合物
JP2019530434A (ja)	2016-08-05	2019-10-24	ジェネンテック，インコーポレイテッド	アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
CN109476748B (zh)	2016-08-08	2023-05-23	豪夫迈·罗氏有限公司	用于癌症的治疗和诊断方法
WO2018031662A1 (en)	2016-08-11	2018-02-15	Genentech, Inc.	Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
WO2018031865A1 (en)	2016-08-12	2018-02-15	Genentech, Inc.	Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor
JP7213549B2 (ja)	2016-08-22	2023-01-27	シーエイチオーファーマインコーポレイテッド	抗体、結合性断片、および使用の方法
BR112019003709A2 (pt)	2016-08-25	2019-05-28	Centre Nat Rech Scient	nanopartículas de silício multifuncionalizadas, usos de nanopartículas de silício multifuncionalizadas, composição e métodos para medir um analito por um método in vitro
WO2018044812A2 (en)	2016-08-29	2018-03-08	Fred Hutchinson Cancer Research Center	Chelating platform for delivery of radionuclides
JP7018210B2 (ja)	2016-09-06	2022-02-10	ザリージェンツオブザユニバーシティオブカリフォルニア	ヒドロキシピリドネートアクチニド／ランタニド体外除去剤の製剤
WO2018049248A1 (en)	2016-09-09	2018-03-15	Icellhealth Consulting Llc	Oncolytic virus equipped with bispecific engager molecules
SG10201607778XA (en)	2016-09-16	2018-04-27	Chugai Pharmaceutical Co Ltd	Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
EP4268845A3 (en)	2016-09-23	2024-02-28	F. Hoffmann-La Roche AG	Uses of il-13 antagonists for treating atopic dermatitis
EP4290532A3 (en)	2016-09-29	2024-03-20	The Regents of the University of California	Separation of metal ions by liquid-liquid extraction
CA3038671A1 (en)	2016-09-29	2018-04-05	Genentech, Inc.	Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a taxane
PL3519437T3 (pl)	2016-09-30	2022-01-17	F. Hoffmann-La Roche Ag	Przeciwciała dwuswoiste przeciwko p95HER2
JP7050770B2 (ja)	2016-10-05	2022-04-08	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	抗体薬物コンジュゲートの調製方法
CN110198743B (zh)	2016-10-05	2023-07-18	艾科赛扬制药股份有限公司	用于治疗肾脏疾病的组合物和方法
JP7579056B2 (ja)	2016-10-06	2024-11-07	ジェネンテック，インコーポレイテッド	がんのための治療方法及び診断方法
WO2018068201A1 (en)	2016-10-11	2018-04-19	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against ctla-4
JP6949468B2 (ja)	2016-10-17	2021-10-13	ルプレヒト−カールス−ウニベルジテートハイデルベルク	腫瘍抗原をコードする麻疹ウイルス
EP3529617B1 (en)	2016-10-24	2023-05-17	Roche Diagnostics GmbH	Immobilized analytes
CN110267678A (zh)	2016-10-29	2019-09-20	霍夫曼-拉罗奇有限公司	抗mic抗体和使用方法
US12109234B2 (en)	2016-11-04	2024-10-08	2Seventy Bio, Inc.	Anti-BCMA CAR T cell compositions
KR20240029119A (ko)	2016-11-15	2024-03-05	제넨테크, 인크.	항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
DK3541833T5 (da)	2016-11-17	2024-09-02	2Seventy Bio Inc	TGFß signalkonverter
TW201829463A (zh)	2016-11-18	2018-08-16	瑞士商赫孚孟拉羅股份公司	抗hla-g抗體及其用途
EP3541414B1 (en)	2016-11-21	2024-08-28	OBI Pharma, Inc.	Conjugated biological molecules, pharmaceutical compositions and methods
MX2019006334A (es)	2016-12-07	2019-08-01	Genentech Inc	Anticuerpos antitau y métodos de uso.
KR20240035636A (ko)	2016-12-07	2024-03-15	제넨테크, 인크.	항-타우 항체 및 이의 이용 방법
CN110114674B (zh)	2016-12-13	2023-05-09	豪夫迈·罗氏有限公司	确定肿瘤样品中存在靶抗原的方法
CN117752798A (zh)	2016-12-19	2024-03-26	豪夫迈·罗氏有限公司	用靶向性4-1bb(cd137)激动剂的组合疗法
CA3039446A1 (en)	2016-12-20	2018-06-28	F. Hoffmann-La Roche Ag	Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
CN108239150A (zh)	2016-12-24	2018-07-03	信达生物制药(苏州)有限公司	抗pcsk9抗体及其用途
KR20210126136A (ko)	2016-12-27	2021-10-19	에프. 호프만-라 로슈 아게	신규한 비오틴-특이적 단일클론 항체 및 그 용도
EP3562841A1 (en)	2016-12-27	2019-11-06	H. Hoffnabb-La Roche Ag	Novel biotin-specific monoclonal antibody and use thereof
EP3562842A1 (en)	2016-12-27	2019-11-06	H. Hoffnabb-La Roche Ag	Novel biotin-specific monoclonal antibody and use thereof
RU2019123613A (ru)	2017-01-03	2021-02-05	Ф. Хоффманн-Ля Рош Аг	Биспецифические антигенсвязывающие молекулы, содержащие антитело к4-1вв, клон 20н4.9
JP7068323B2 (ja)	2017-02-02	2022-05-16	エフ．ホフマン－ラロシュアーゲー	少なくとも２種のペグ化された分析物特異的結合剤を使用する免疫アッセイ
CA3051169A1 (en)	2017-02-03	2018-08-09	Acticor Biotech	Inhibition of platelet aggregation using anti-human gpvi antibodies
AU2018217816A1 (en)	2017-02-10	2019-08-15	Genentech, Inc.	Anti-tryptase antibodies, compositions thereof, and uses thereof
CN110546277B (zh)	2017-03-01	2024-06-11	豪夫迈·罗氏有限公司	用于癌症的诊断和治疗方法
AU2018240375C1 (en)	2017-03-22	2024-02-01	Ascendis Pharma A/S	Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
AR111249A1 (es)	2017-03-22	2019-06-19	Genentech Inc	Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares
CN108623686A (zh)	2017-03-25	2018-10-09	信达生物制药(苏州)有限公司	抗ox40抗体及其用途
MX2019011526A (es)	2017-03-27	2019-12-05	Hoffmann La Roche	Receptores de union a antigeno mejorados.
WO2018177967A1 (en)	2017-03-27	2018-10-04	F. Hoffmann-La Roche Ag	Improved antigen binding receptor formats
SG11201908326YA (en)	2017-03-28	2019-10-30	Genentech Inc	Methods of treating neurodegenerative diseases
WO2018178074A1 (en)	2017-03-29	2018-10-04	F. Hoffmann-La Roche Ag	Trimeric antigen binding molecules specific for a costimulatory tnf receptor
WO2018178055A1 (en)	2017-03-29	2018-10-04	F. Hoffmann-La Roche Ag	Bispecific antigen binding molecule for a costimulatory tnf receptor
CN110382542B (zh)	2017-03-29	2023-06-09	豪夫迈·罗氏有限公司	针对共刺激性tnf受体的双特异性抗原结合分子
EP3606947B1 (en)	2017-04-03	2022-12-21	F. Hoffmann-La Roche AG	Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
CN110494452B (zh)	2017-04-03	2023-08-25	豪夫迈·罗氏有限公司	结合steap-1的抗体
AU2018247765B2 (en)	2017-04-03	2023-11-23	F. Hoffmann-La Roche Ag	Immunoconjugates of an Anti-PD-1 antibody with a mutant IL-2 or with IL-15
SG11201908787WA (en)	2017-04-04	2019-10-30	Hoffmann La Roche	Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
PT3606955T (pt)	2017-04-05	2025-01-09	Hoffmann La Roche	Anticorpos biespecíficos que se ligam especificamente a pd1 e a lag3
DK3606954T3 (en)	2017-04-05	2022-09-26	Hoffmann La Roche	Anti-LAG3-antistoffer
JP6977058B2 (ja)	2017-04-12	2021-12-08	エフ.ホフマン−ラロシュアーゲーF. Hoffmann−La Roche Aktiengesellschaft	ピクテ・スペングラー反応を介して得られたタグ付けヌクレオシドを用いたシーケンシング反応のための方法
AU2018250875A1 (en)	2017-04-13	2019-10-03	F. Hoffmann-La Roche Ag	An interleukin-2 immunoconjugate, a CD40 agonist, and optionally a PD-1 axis binding antagonist for use in methods of treating cancer
CN108728444A (zh)	2017-04-18	2018-11-02	长春华普生物技术股份有限公司	免疫调节性多核苷酸及其应用
WO2018195472A1 (en)	2017-04-21	2018-10-25	Genentech, Inc.	Use of klk5 antagonists for treatment of a disease
EP3615572A1 (en)	2017-04-27	2020-03-04	Tesaro Inc.	Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
EP3625251A1 (en)	2017-05-15	2020-03-25	University Of Rochester	Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
EP3409322A1 (en)	2017-06-01	2018-12-05	F. Hoffmann-La Roche AG	Treatment method
WO2018224439A1 (en)	2017-06-05	2018-12-13	Numab Innovation Ag	Novel anti-hsa antibodies
WO2018224441A1 (en)	2017-06-05	2018-12-13	Numab Innovation Ag	Novel anti-cd3 antibodies
WO2019000223A1 (en)	2017-06-27	2019-01-03	Nanjing Legend Biotech Co., Ltd.	ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
JP2020527351A (ja)	2017-07-21	2020-09-10	ジェネンテック，インコーポレイテッド	がんの治療法及び診断法
KR20200036889A (ko)	2017-07-28	2020-04-07	에프. 호프만-라 로슈 아게	이중특이성 항체 제형
MY205541A (en)	2017-08-03	2024-10-25	Alector Llc	Anti-cd33 antibodies and methods of use thereof
CN109422811A (zh)	2017-08-29	2019-03-05	信达生物制药(苏州)有限公司	抗cd47抗体及其用途
EP3459970A1 (en)	2017-09-20	2019-03-27	Universität Heidelberg	Norovirus nanobodies
WO2019059411A1 (en)	2017-09-20	2019-03-28	Chugai Seiyaku Kabushiki Kaisha	DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
EP3459968A1 (en)	2017-09-20	2019-03-27	Numab Innovation AG	Novel stable antibody variable domain framework combinations
JP6496095B1 (ja)	2017-09-29	2019-04-03	中外製薬株式会社	血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）補因子機能代替活性を有する多重特異性抗原結合分子および当該分子を有効成分として含有する薬学的製剤
EP3470428A1 (en)	2017-10-10	2019-04-17	Numab Innovation AG	Antibodies targeting cd137 and methods of use thereof
KR20200063147A (ko)	2017-10-10	2020-06-04	누맙 세러퓨틱스 아게	Pdl1 표적화 항체 및 이의 사용 방법
JP7438939B2 (ja)	2017-10-10	2024-02-27	ヌマブセラピューティクスアクチェンゲゼルシャフト	Ｃｄ１３７を標的とする抗体とその利用方法
EP3470426A1 (en)	2017-10-10	2019-04-17	Numab Therapeutics AG	Multispecific antibody
EP3470429A1 (en)	2017-10-10	2019-04-17	Numab Innovation AG	Antibodies targeting pdl1 and methods of use thereof
SG11202002982YA (en)	2017-10-10	2020-04-29	Numab Therapeutics AG	Multispecific antibody
CN111246885B (zh)	2017-10-20	2024-06-11	豪夫迈·罗氏有限公司	从单特异性抗体生成多特异性抗体的方法
TWI832824B (zh)	2017-10-30	2024-02-21	瑞士商赫孚孟拉羅股份公司	自單特異性抗體於活體內產生多特異性抗體之方法
CN111246884A (zh)	2017-11-01	2020-06-05	豪夫迈·罗氏有限公司	新颖的含有tnf家族配体三聚体的抗原结合分子
CN111182944B (zh)	2017-11-01	2022-11-22	豪夫迈·罗氏有限公司	双特异性2+1 Contorsbody
BR112020007630A2 (pt)	2017-11-01	2020-11-17	F. Hoffmann-La Roche Ag	anticorpo biespecífico ox40, produto farmacêutico, composição farmacêutica e anticorpos biespecíficos anti-fap/ anti-ox40
EP3707510B1 (en)	2017-11-06	2024-06-26	F. Hoffmann-La Roche AG	Diagnostic and therapeutic methods for cancer
CA3079039A1 (en)	2017-12-14	2019-06-20	F. Hoffmann-La Roche Ag	Use of a cea cd3 bispecific antibody and a pd-1 axis binding antagonist in a dosage regime to treat cancer
WO2019122046A1 (en)	2017-12-21	2019-06-27	F. Hoffmann-La Roche Ag	Universal reporter cell assay for specificity test of novel antigen binding moieties
US11192957B2 (en)	2017-12-21	2021-12-07	Hoffmann-La Roche Inc.	Antibodies binding to HLA-A2/WT1
EP3502140A1 (en)	2017-12-21	2019-06-26	F. Hoffmann-La Roche AG	Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
CN111492243B (zh)	2017-12-21	2024-11-01	豪夫迈·罗氏有限公司	用于新颖抗原结合模块的特异性测试的car-t细胞测定法
WO2019126472A1 (en)	2017-12-22	2019-06-27	Genentech, Inc.	Use of pilra binding agents for treatment of a disease
WO2019129136A1 (zh)	2017-12-27	2019-07-04	信达生物制药(苏州)有限公司	抗pd-l1抗体及其用途
WO2019129137A1 (zh)	2017-12-27	2019-07-04	信达生物制药(苏州)有限公司	抗lag-3抗体及其用途
CN115925943A (zh)	2017-12-27	2023-04-07	信达生物制药(苏州)有限公司	抗pd-l1抗体及其用途
CA3078849A1 (en)	2017-12-28	2019-07-04	Nanjing Legend Biotech Co., Ltd.	Antibodies and variants thereof against pd-l1
JP2021508471A (ja)	2017-12-29	2021-03-11	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	抗ｖｅｇｆ抗体のｖｅｇｆ受容体遮断選択性を改善する方法
JP7490565B2 (ja)	2017-12-29	2024-05-27	アレクトルエルエルシー	抗ｔｍｅｍ１０６ｂ抗体及びその使用方法
WO2019139987A1 (en)	2018-01-09	2019-07-18	Elstar Therapeutics, Inc.	Calreticulin binding constructs and engineered t cells for the treatment of diseases
SG11202004233UA (en)	2018-01-15	2020-06-29	Nanjing Legend Biotech Co Ltd	Single-domain antibodies and variants thereof against pd-1
EP3740505A1 (en)	2018-01-16	2020-11-25	Lakepharma Inc.	Bispecific antibody that binds cd3 and another target
WO2019149715A1 (en)	2018-01-31	2019-08-08	F. Hoffmann-La Roche Ag	Stabilized immunoglobulin domains
CN111655730A (zh)	2018-01-31	2020-09-11	豪夫迈·罗氏有限公司	包含与lag3结合的抗原结合位点的双特异性抗体
JP7268038B2 (ja)	2018-01-31	2023-05-02	アレクトルエルエルシー	抗ｍｓ４ａ４ａ抗体及びその使用方法
CA3081125A1 (en)	2018-02-01	2019-08-08	Innovent Biologics (Suzhou) Co., Ltd.	Fully humanized anti-b cell maturation antigen (bcma) single-chain antibody and use thereof
CA3089287A1 (en)	2018-02-08	2019-08-15	Genentech, Inc.	Bispecific antigen-binding molecules and methods of use
KR20220098056A (ko)	2018-02-09	2022-07-08	제넨테크, 인크.	비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
CA3090538A1 (en)	2018-02-09	2019-08-15	Acceleron Pharma, Inc.	Methods for treating heterotopic ossification
TWI829667B (zh)	2018-02-09	2024-01-21	瑞士商赫孚孟拉羅股份公司	結合gprc5d之抗體
KR20200135313A (ko)	2018-02-26	2020-12-02	제넨테크, 인크.	항-tigit 및 항-pd-l1 길항제 항체에 의한 치료를 위한 투약
JP2021514648A (ja)	2018-03-01	2021-06-17	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	新規の標的抗原結合部分のための特異性アッセイ
TWI841551B (zh)	2018-03-13	2024-05-11	瑞士商赫孚孟拉羅股份公司	使用靶向4-1bb (cd137)之促效劑的組合療法
BR112020015568A2 (pt)	2018-03-13	2020-12-29	F. Hoffmann-La Roche Ag	Agonista de 4-1bb (cd137), produto farmacêutico, composição farmacêutica, uso de uma combinação de um agonista de 4-1bb e método para tratar ou retardar a progressão do câncer
US20200040103A1 (en)	2018-03-14	2020-02-06	Genentech, Inc.	Anti-klk5 antibodies and methods of use
WO2019178362A1 (en)	2018-03-14	2019-09-19	Elstar Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
KR102411489B1 (ko)	2018-03-14	2022-06-23	서피스 온콜로지, 인크.	Cd39에 결합하는 항체 및 이의 용도
WO2019177543A1 (en)	2018-03-15	2019-09-19	Chugai Seiyaku Kabushiki Kaisha	Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
KR20200135510A (ko)	2018-03-29	2020-12-02	제넨테크, 인크.	포유류 세포들에서 젖분비자극 활성의 조절
EP3778639A4 (en)	2018-04-02	2021-06-09	Mab-Venture Biopharm Co., Ltd.	ANTIBODIES BINDING TO LYMPHOCYTAIR ACTIVATION GENE 3 (LAG-3) AND ITS USE
JP2021520209A (ja)	2018-04-04	2021-08-19	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	癌患者における腫瘍抗原を検出するための診断アッセイ
CN111742220A (zh)	2018-04-04	2020-10-02	豪夫迈·罗氏有限公司	检测癌症患者中的肿瘤抗原的诊断性测定法
TW202011029A (zh)	2018-04-04	2020-03-16	美商建南德克公司	偵測及定量fgf21之方法
CN111741979B (zh)	2018-04-13	2024-07-02	豪夫迈·罗氏有限公司	包含4-1BBL的Her2靶向性抗原结合分子
AR115052A1 (es)	2018-04-18	2020-11-25	Hoffmann La Roche	Anticuerpos multiespecíficos y utilización de los mismos
AR114789A1 (es)	2018-04-18	2020-10-14	Hoffmann La Roche	Anticuerpos anti-hla-g y uso de los mismos
EP3787678A1 (en)	2018-05-03	2021-03-10	University Of Rochester	Anti-influenza neuraminidase monoclonal antibodies and uses thereof
US20190345261A1 (en)	2018-05-10	2019-11-14	Sensei Biotherapeutics, Inc.	Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof
AU2019269066B2 (en)	2018-05-18	2022-10-06	F. Hoffmann-La Roche Ag	Targeted intracellular delivery of large nucleic acids
SG11202011082UA (en)	2018-05-25	2020-12-30	Alector Llc	Anti-sirpa antibodies and methods of use thereof
WO2019235426A1 (ja)	2018-06-04	2019-12-12	中外製薬株式会社	細胞質内での半減期が変化した抗原結合分子
WO2019233842A1 (en)	2018-06-08	2019-12-12	F. Hoffmann-La Roche Ag	Peptidic linker with reduced post-translational modification
ES2977415T3 (es)	2018-06-14	2024-08-23	Regeneron Pharma	Receptores de antígenos quiméricos contra CD79A
KR20210020900A (ko)	2018-06-14	2021-02-24	블루버드 바이오, 인코포레이티드.	항-bcma car 항체, 접합체 및 사용 방법
KR20210024550A (ko)	2018-06-23	2021-03-05	제넨테크, 인크.	Pd-1 축 결합 길항제, 백금 제제, 및 토포이소머라제 ii 억제제를 이용한 폐암 치료 방법
US11203645B2 (en)	2018-06-27	2021-12-21	Obi Pharma, Inc.	Glycosynthase variants for glycoprotein engineering and methods of use
EA202190138A1 (ru)	2018-06-29	2021-05-27	ЭЛЕКТОР ЭлЭлСи	Анти-sirp-бета1 антитела и способы их использования
TW202035447A (zh)	2018-07-04	2020-10-01	瑞士商赫孚孟拉羅股份公司	新穎雙特異性促效性4-1bb抗原結合分子
BR112021000249A2 (pt)	2018-07-11	2021-04-06	Celgene Corporation	Usos de receptores de antígeno quimérico anti-bcma
SG11202012339WA (en)	2018-07-13	2021-01-28	Nanjing Legend Biotech Co Ltd	Co-receptor systems for treating infectious diseases
ES2940311T3 (es)	2018-07-13	2023-05-05	Alector Llc	Anticuerpos anti-sortilina y métodos de uso de los mismos
GB201811597D0 (en)	2018-07-16	2018-08-29	Hemogad Tech Ltd	Analyser
EP3823611A1 (en)	2018-07-18	2021-05-26	Genentech, Inc.	Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
JP7072715B2 (ja)	2018-07-20	2022-05-20	サーフィスオンコロジーインコーポレイテッド	抗ｃｄ１１２ｒ組成物及び方法
CA3106829A1 (en)	2018-08-03	2020-02-06	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule containing two antigen-binding domains that are linked to each other
SG11202100601TA (en)	2018-08-08	2021-02-25	Genentech Inc	Use of tryptophan derivatives and l-methionine for protein formulation
MX2021001431A (es)	2018-08-10	2021-05-12	Chugai Pharmaceutical Co Ltd	Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso.
TW202021618A (zh)	2018-08-17	2020-06-16	美商２３與我有限公司	抗ｉｌ１ｒａｐ抗體及其使用方法
TW202016307A (zh)	2018-08-31	2020-05-01	美商阿列克特有限責任公司	抗cd33 抗體及其使用方法
GB201814281D0 (en)	2018-09-03	2018-10-17	Femtogenix Ltd	Cytotoxic agents
TWI841595B (zh)	2018-09-10	2024-05-11	大陸商南京傳奇生物科技有限公司	針對ｃｄ３３之單域抗體及其構築體
TWI846731B (zh)	2018-09-18	2024-07-01	瑞士商赫孚孟拉羅股份公司	組織蛋白酶(cathepsin)S抑制劑之對抗抗藥抗體形成之用途
JP2022501332A (ja)	2018-09-19	2022-01-06	ジェネンテック，インコーポレイテッド	膀胱がんの治療方法および診断方法
EP4249917A3 (en)	2018-09-21	2023-11-08	F. Hoffmann-La Roche AG	Diagnostic methods for triple-negative breast cancer
JP7221379B2 (ja)	2018-10-01	2023-02-13	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	抗ｆａｐクローン２１２を含む二重特異性抗原結合分子
JP2022511396A (ja)	2018-10-01	2022-01-31	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	Ｃｄ４０への三価結合を伴う二重特異性抗原結合分子
EP3636320A1 (en)	2018-10-09	2020-04-15	Numab Therapeutics AG	Antibodies targeting cd137 and methods of use thereof
TWI839395B (zh)	2018-10-09	2024-04-21	瑞士商Ｎｕｍａｂ治療公司	靶向cd137的抗體及其使用方法
TW202028244A (zh)	2018-10-09	2020-08-01	美商建南德克公司	用於確定突觸形成之方法及系統
KR20210079311A (ko)	2018-10-18	2021-06-29	제넨테크, 인크.	육종성 신장암에 대한 진단과 치료 방법
IL282441B1 (en)	2018-10-24	2025-03-01	Hoffmann La Roche	Combined chemical influencing factors of decomposition and methods of use
SG11202104104VA (en)	2018-11-05	2021-05-28	Genentech Inc	Methods of producing two chain proteins in prokaryotic host cells
EP3880837A1 (en)	2018-11-16	2021-09-22	F. Hoffmann-La Roche AG	Streptavidin-coated solid phases with a member of a binding pair
CA3119798A1 (en)	2018-12-06	2020-06-11	Genentech, Inc.	Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody
WO2020123275A1 (en)	2018-12-10	2020-06-18	Genentech, Inc.	Photocrosslinking peptides for site specific conjugation to fc-containing proteins
AR117327A1 (es)	2018-12-20	2021-07-28	23Andme Inc	Anticuerpos anti-cd96 y métodos de uso de estos
PH12021551484A1 (en)	2018-12-21	2022-04-11	Hoffmann La Roche	Antibodies binding to cd3
JP7560459B2 (ja)	2018-12-21	2024-10-02	ジェネンテック，インコーポレイテッド	アポトーシスに耐性のある細胞株を使用してポリペプチドを生成する方法
CA3120474A1 (en)	2018-12-21	2020-06-25	23Andme, Inc.	Anti-il-36 antibodies and methods of use thereof
WO2020127618A1 (en)	2018-12-21	2020-06-25	F. Hoffmann-La Roche Ag	Tumor-targeted agonistic cd28 antigen binding molecules
EP3898683A1 (en)	2018-12-21	2021-10-27	F. Hoffmann-La Roche AG	Tumor-targeted superagonistic cd28 antigen binding molecules
CN113272327A (zh)	2018-12-30	2021-08-17	豪夫迈·罗氏有限公司	抗兔cd19抗体及其使用方法
US20220073626A1 (en)	2019-01-03	2022-03-10	Institut National De La Santé Et De La Recheche Médicale (Inserm)	Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
WO2020150152A1 (en)	2019-01-14	2020-07-23	Genentech, Inc.	Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine
CA3124515A1 (en)	2019-01-23	2020-07-30	Genentech, Inc.	Methods of producing multimeric proteins in eukaryotic host cells
CN113329770A (zh)	2019-01-24	2021-08-31	中外制药株式会社	新型癌抗原及所述抗原的抗体
GB201901197D0 (en)	2019-01-29	2019-03-20	Femtogenix Ltd	G-A Crosslinking cytotoxic agents
JP7525499B2 (ja)	2019-01-31	2024-07-30	ヌマブセラピューティクスアクチェンゲゼルシャフト	ＴＮＦα及びＩＬ－１７Ａに対する特異性を有する多重特異性抗体、ＩＬ－１７Ａを標的とする抗体、及びそれらの使用方法
EP3689907A1 (en)	2019-01-31	2020-08-05	Numab Therapeutics AG	Antibodies targeting il-17a and methods of use thereof
WO2020163589A1 (en)	2019-02-08	2020-08-13	Genentech, Inc.	Diagnostic and therapeutic methods for cancer
WO2020169698A1 (en)	2019-02-21	2020-08-27	F. Hoffmann-La Roche Ag	Sensitization of cancer cells to tnf by bet inhibition
EP3931220A1 (en)	2019-02-27	2022-01-05	F. Hoffmann-La Roche AG	Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
EP3930744A1 (en)	2019-03-01	2022-01-05	Allogene Therapeutics, Inc.	Dll3 targeting chimeric antigen receptors and binding agents
CA3126728A1 (en)	2019-03-08	2020-09-17	Genentech, Inc.	Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles
KR20210141555A (ko)	2019-03-14	2021-11-23	제넨테크, 인크.	Her2xcd3 이중특이적 항체 및 항-her2 mab를 병용한 암의 치료
KR20210141997A (ko)	2019-03-18	2021-11-23	도이체스 크렙스포르슝스첸트룸	세포의 유전적 변형을 위한 발현 작제물
CN113677403B (zh)	2019-04-12	2024-12-27	豪夫迈·罗氏有限公司	包含脂质运载蛋白突变蛋白的双特异性抗原结合分子
EP3953386A1 (en)	2019-04-12	2022-02-16	F. Hoffmann-La Roche AG	Treatment of cancer using a cea cd3 bispecific antibody and a wnt signaling inhibitor
KR20220002967A (ko)	2019-04-19	2022-01-07	제넨테크, 인크.	항 mertk 항체 및 이의 사용 방법
US12163153B2 (en)	2019-04-26	2024-12-10	Allogene Therapeutics, Inc.	Methods of manufacturing allogeneic CAR T cells
TW202108616A (zh)	2019-05-03	2021-03-01	美商建南德克公司	用抗pd-l1抗體治療癌症之方法
CN114206340A (zh)	2019-05-14	2022-03-18	豪夫迈·罗氏有限公司	使用抗cd79b免疫缀合物治疗滤泡性淋巴瘤的方法
KR20220031616A (ko)	2019-06-11	2022-03-11	알렉터 엘엘씨	치료요법에 사용하기 위한 항-소르틸린 항체
EP3990477A1 (en)	2019-06-26	2022-05-04	F. Hoffmann-La Roche AG	Fusion of an antibody binding cea and 4-1bbl
JP7354306B2 (ja)	2019-06-27	2023-10-02	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	新規ｉｃｏｓ抗体及びそれらを含む腫瘍標的化抗原結合分子
WO2021001289A1 (en)	2019-07-02	2021-01-07	F. Hoffmann-La Roche Ag	Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
AR119393A1 (es)	2019-07-15	2021-12-15	Hoffmann La Roche	Anticuerpos que se unen a nkg2d
WO2021022083A2 (en)	2019-07-31	2021-02-04	Alector Llc	Anti-ms4a4a antibodies and methods of use thereof
MX2022001156A (es)	2019-07-31	2022-02-22	Hoffmann La Roche	Anticuerpos que se fijan a gprc5d.
EP4004045A1 (en)	2019-07-31	2022-06-01	F. Hoffmann-La Roche AG	Antibodies binding to gprc5d
EP4438057A3 (en)	2019-09-12	2025-01-01	F. Hoffmann-La Roche AG	Compositions and methods of treating lupus nephritis
US20220372160A1 (en)	2019-09-16	2022-11-24	Surface Oncology, Inc.	Anti-CD39 Antibody Compositions and Methods
CA3150999A1 (en)	2019-09-18	2021-03-25	James Thomas Koerber	Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
CA3147179A1 (en)	2019-09-20	2021-03-25	Joseph Haw-Ling Lin	Dosing for anti-tryptase antibodies
WO2021057978A1 (zh)	2019-09-27	2021-04-01	南京金斯瑞生物科技有限公司	抗vhh域抗体及其用途
KR20220070237A (ko)	2019-09-27	2022-05-30	제넨테크, 인크.	항-tigit 및 항-pd-l1 길항제 항체를 이용한 치료를 위한 투약
CA3153880A1 (en)	2019-10-18	2020-06-09	Juana Elva HERNANDEZ MONTALVO	Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
EP3816185A1 (en)	2019-11-04	2021-05-05	Numab Therapeutics AG	Multispecific antibody directed against pd-l1 and a tumor-associated antigen
JP2023501276A (ja)	2019-11-05	2023-01-18	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	Ｈｌａ－ａ２／ｗｔ１×ｃｄ３二重特異性抗体及びレナリドマイドを使用するがんの治療
BR112022008522A2 (pt)	2019-11-05	2022-07-26	Celgene Corp	Usos de receptores de antígeno quimérico anti-bcma
IL292458A (en)	2019-11-06	2022-06-01	Genentech Inc	Diagnostic and treatment methods for the treatment of hematological cancer
CR20220322A (es)	2019-12-09	2022-07-28	Genentech Inc	Formulaciones de anticuerpos anti-pd-l1
US10980836B1 (en)	2019-12-11	2021-04-20	Myeloid Therapeutics, Inc.	Therapeutic cell compositions and methods of manufacturing and use thereof
TW202136303A (zh)	2019-12-13	2021-10-01	美商阿列克特有限責任公司	抗mertk抗體及其使用方法
AU2020403145A1 (en)	2019-12-13	2022-07-07	Genentech, Inc.	Anti-Ly6G6D antibodies and methods of use
WO2021122875A1 (en)	2019-12-18	2021-06-24	F. Hoffmann-La Roche Ag	Antibodies binding to hla-a2/mage-a4
EP4081294A2 (en)	2019-12-23	2022-11-02	Genentech, Inc.	Apolipoprotein l1-specific antibodies and methods of use
US20230058982A1 (en)	2019-12-27	2023-02-23	Chugai Seiyaku Kabushiki Kaisha	Anti-ctla-4 antibody and use thereof
JP2023509952A (ja)	2020-01-09	2023-03-10	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	新規４－１ｂｂｌ三量体含有抗原結合分子
CN110818795B (zh)	2020-01-10	2020-04-24	上海复宏汉霖生物技术股份有限公司	抗tigit抗体和使用方法
WO2021194481A1 (en)	2020-03-24	2021-09-30	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2022050954A1 (en)	2020-09-04	2022-03-10	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
BR112022015077A2 (pt)	2020-01-31	2022-10-04	Genentech Inc	Métodos para induzir células t cd8+ específicas de neoepítopos em um indivíduo com um tumor e para induzir o tráfico de células t cd8+, vacinas de rna, vacina de rna para uso e antagonistas de ligação
US20230312704A1 (en)	2020-02-10	2023-10-05	Shanghai Escugen Biotechnology Co., Ltd.	Cldn18.2 antibody and use thereof
AU2021218927B2 (en)	2020-02-10	2024-12-19	Shanghai Escugen Biotechnology Co., Ltd.	Claudin 18.2 antibody and use thereof
TW202144395A (zh)	2020-02-12	2021-12-01	日商中外製藥股份有限公司	用於癌症之治療的抗cd137抗原結合分子
DE102020111571A1 (de)	2020-03-11	2021-09-16	Immatics US, Inc.	Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
CN115605507A (zh)	2020-03-13	2023-01-13	基因泰克公司（Us）	抗白介素-33抗体及其用途
PH12022552326A1 (en)	2020-03-19	2023-11-29	Genentech Inc	Isoform-selective anti-tgf-beta antibodies and methods of use
CN115867649A (zh)	2020-03-24	2023-03-28	基因泰克公司	Tie2结合剂及其使用方法
KR20220159426A (ko)	2020-03-26	2022-12-02	제넨테크, 인크.	감소된 숙주 세포 단백질을 보유하는 변형된 포유동물 세포
CN116075525A (zh)	2020-03-31	2023-05-05	艾莱克特有限责任公司	抗mertk抗体及其使用方法
CA3173519A1 (en)	2020-03-31	2021-10-07	Vishnu Priyanka Reddy CHICHILI	Method for producing multispecific antigen-binding molecules
AR121706A1 (es)	2020-04-01	2022-06-29	Hoffmann La Roche	Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
EP4126934A1 (en)	2020-04-01	2023-02-08	University of Rochester	Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
WO2021202959A1 (en)	2020-04-03	2021-10-07	Genentech, Inc.	Therapeutic and diagnostic methods for cancer
BR112022020629A2 (pt)	2020-04-15	2022-11-29	Hoffmann La Roche	Polipeptídeo de interleucina-7 (il-7) mutante, imunoconjugado, um ou mais polinucleotídeos isolados, célula hospedeira, métodos para produzir um polipeptídeo il-7 mutante ou um imunoconjugado, para tratar uma doença e para estimular o sistema imunológico, polipeptídeo il-7 mutante, composição farmacêutica, uso do polipeptídeo il-7 mutante e invenção
BR112022021203A2 (pt)	2020-04-24	2022-12-06	Hoffmann La Roche	Modulação de enzima e via com compostos sulfidrila e seus derivados
AU2021259861A1 (en)	2020-04-24	2022-11-17	Genentech, Inc.	Methods of using anti-CD79b immunoconjugates
JP2023523450A (ja)	2020-04-28	2023-06-05	ジェネンテック，インコーポレイテッド	非小細胞肺がん免疫療法のための方法及び組成物
EP3921034A2 (en)	2020-04-28	2021-12-15	The Rockefeller University	Neutralizing anti-sars-cov-2 antibodies and methods of use thereof
KR20230087414A (ko)	2020-05-03	2023-06-16	레베나 (쑤저우) 바이오파마 컴퍼니 리미티드	항-Trop-2 항체를 포함하는 항체-약물 접합체 (ADCS), 상기 ADCS를 포함하는 조성물, 및 이의 제조 및 사용 방법
WO2021229103A2 (en)	2020-05-15	2021-11-18	Apogenix Ag	Multi-specific immune modulators
EP3915580A1 (en)	2020-05-29	2021-12-01	Numab Therapeutics AG	Multispecific antibody
IL298668A (en)	2020-05-29	2023-01-01	23Andme Inc	Anti-cd200r1 antibodies and methods of use thereof
CA3184495A1 (en)	2020-06-08	2021-12-16	F. Hoffmann-La Roche Ag	Anti-hbv antibodies and methods of use
CN115803063A (zh)	2020-06-11	2023-03-14	基因泰克公司	纳米脂蛋白-多肽缀合物和组合物、系统以及其使用方法
WO2021252977A1 (en)	2020-06-12	2021-12-16	Genentech, Inc.	Methods and compositions for cancer immunotherapy
IL299039A (en)	2020-06-16	2023-02-01	Genentech Inc	Methods and preparations for the treatment of triple-negative breast cancer
CN115916348A (zh)	2020-06-18	2023-04-04	基因泰克公司	使用抗tigit抗体和pd-1轴结合拮抗剂的治疗
CN115916825A (zh)	2020-06-19	2023-04-04	豪夫迈·罗氏有限公司	与cd3和cd19结合的抗体
WO2021255146A1 (en)	2020-06-19	2021-12-23	F. Hoffmann-La Roche Ag	Antibodies binding to cd3 and cea
PE20231552A1 (es)	2020-06-19	2023-10-03	Hoffmann La Roche	Anticuerpos biespecificos para linfocitos t activados por proteasa
JP2023530961A (ja)	2020-06-19	2023-07-20	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	Ｃｄ３に結合する抗体
KR20230025673A (ko)	2020-06-19	2023-02-22	에프. 호프만-라 로슈 아게	CD3 및 FolR1에 결합하는 항체
US20230235040A1 (en)	2020-06-22	2023-07-27	Almirall, S.A.	Anti-il-36 antibodies and methods of use thereof
PE20231361A1 (es)	2020-06-23	2023-09-05	Hoffmann La Roche	Moleculas agonistas de union al antigeno cd28 que se dirigen a her2
MX2022016453A (es)	2020-06-24	2023-02-01	Genentech Inc	Lineas celulares resistentes a la apoptosis.
CN115916830A (zh)	2020-06-25	2023-04-04	豪夫迈·罗氏有限公司	抗cd3/抗cd28双特异性抗原结合分子
EP4179332A1 (en)	2020-07-13	2023-05-17	Genentech, Inc.	Cell-based methods for predicting polypeptide immunogenicity
US20230303682A1 (en)	2020-07-17	2023-09-28	Genentech, Inc.	Anti-Notch2 Antibodies and Methods of Use
KR20230042032A (ko)	2020-07-21	2023-03-27	제넨테크, 인크.	Brm 분해의 항체 접합 화학 유도제 및 이의 방법
GB2597532A (en)	2020-07-28	2022-02-02	Femtogenix Ltd	Cytotoxic compounds
JP2023537683A (ja)	2020-08-07	2023-09-05	ジェネンテック，インコーポレイテッド	ポリペプチド免疫原性を予測するためのｔ細胞ベースの方法
EP4196612A1 (en)	2020-08-12	2023-06-21	Genentech, Inc.	Diagnostic and therapeutic methods for cancer
US20220056411A1 (en)	2020-08-21	2022-02-24	Immatics US, Inc.	Methods for isolating cd8+ selected t cells
KR20230056766A (ko)	2020-08-28	2023-04-27	제넨테크, 인크.	숙주 세포 단백질의 CRISPR/Cas9 다중 녹아웃
CN116113707A (zh)	2020-08-31	2023-05-12	基因泰克公司	用于产生抗体的方法
JP2023541627A (ja)	2020-09-14	2023-10-03	イシュノスサイエンシズソシエテアノニム	Ｉｌ１ｒａｐに結合する抗体及びその使用
KR20230074146A (ko)	2020-09-24	2023-05-26	에프. 호프만-라 로슈 아게	T 세포 이중특이성 항체 관련 역효과의 예방 또는 완화
TW202446417A (zh)	2020-10-05	2024-12-01	美商建南德克公司	用抗 fcrh5/抗 cd3 雙特異性抗體進行治療之給藥
IL300024A (en)	2020-10-20	2023-03-01	Hoffmann La Roche	Combination therapy of PD-1 axis binding antagonists and LRRK2 inhibitors
WO2022086957A1 (en)	2020-10-20	2022-04-28	Genentech, Inc.	Peg-conjugated anti-mertk antibodies and methods of use
EP3988568A1 (en)	2020-10-21	2022-04-27	Numab Therapeutics AG	Combination treatment
WO2022093981A1 (en)	2020-10-28	2022-05-05	Genentech, Inc.	Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
WO2022090439A1 (en)	2020-10-30	2022-05-05	F. Hoffmann-La Roche Ag	TREATMENT OF CANCER USING A CEA CD3 BISPECIFIC ANTIBODY AND A TGFβ SIGNALING INHIBITOR
MX2023005131A (es)	2020-11-04	2023-05-25	Genentech Inc	Dosis para el tratamiento con anticuerpos biespecificos anti-cd20/anti-cd3 y conjugados anticuerpo farmaco anti-cd79b.
WO2022098638A2 (en)	2020-11-04	2022-05-12	Genentech, Inc.	Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
JP2023550309A (ja)	2020-11-04	2023-12-01	セルジーンコーポレーション	以前に抗がんアルキル化剤療法を受けた患者におけるｃａｒｔ細胞療法
US11919945B2 (en)	2020-11-04	2024-03-05	The Rockefeller University	Neutralizing anti-SARS-CoV-2 antibodies
IL302639A (en)	2020-11-04	2023-07-01	Myeloid Therapeutics Inc	Engineered chimeric fusion protein compositions and methods of use thereof
MX2023005130A (es)	2020-11-04	2023-05-25	Genentech Inc	Dosis subcutanea de anticuerpos biespecificos anti-cd20/anti-cd3.
CA3196810A1 (en)	2020-11-10	2022-05-19	F. Hoffmann-La Roche Ag	Prevention or mitigation of t-cell engaging agent-related adverse effects
CR20230253A (es)	2020-11-16	2023-07-26	Hoffmann La Roche	Glucoformas de fab ricas en manosa
JP2023549316A (ja)	2020-11-16	2023-11-24	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	Ｆａｐを標的としたｃｄ４０アゴニストとの併用療法
US20240101681A1 (en)	2020-12-02	2024-03-28	Alector Llc	Methods of use of anti-sortilin antibodies
US20240092853A1 (en)	2020-12-04	2024-03-21	Hoffmann-La Roche Inc.	Ph-dependent mutant interleukin-2 polypeptides
JP2023552773A (ja)	2020-12-04	2023-12-19	セルジーンコーポレーション	炎症関連可溶性因子の阻害剤と組み合わせたキメラ抗原受容体（ｃａｒ）ｔ細胞療法の使用
EP4263609A1 (en)	2020-12-17	2023-10-25	F. Hoffmann-La Roche AG	Anti-hla-g antibodies and use thereof
WO2022148732A1 (en)	2021-01-06	2022-07-14	F. Hoffmann-La Roche Ag	Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
EP4277926A1 (en)	2021-01-15	2023-11-22	The Rockefeller University	Neutralizing anti-sars-cov-2 antibodies
US20240101717A1 (en)	2021-01-22	2024-03-28	Bionecure Therapeutics, Inc.	Anti-her-2/trop-2 constructs and uses thereof
WO2022162587A1 (en)	2021-01-27	2022-08-04	Centre Hospitalier Universitaire Vaudois (C.H.U.V.)	Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
AU2022215847A1 (en)	2021-02-02	2023-08-10	Numab Therapeutics AG	Multispecific antibodies having specificity for ror1 and cd3
CA3210069A1 (en)	2021-03-03	2022-09-09	Tong Zhu	Antibody-drug conjugates comprising an anti-bcma antibody
WO2022192647A1 (en)	2021-03-12	2022-09-15	Genentech, Inc.	Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
CA3213599A1 (en)	2021-03-15	2022-09-22	Genentech, Inc.	Compositions and methods of treating lupus nephritis
JP2024512004A (ja)	2021-03-17	2024-03-18	マイエロイド・セラピューティクス，インコーポレーテッド	操作されたキメラ融合タンパク質組成物およびその使用方法
CN116981696A (zh)	2021-03-18	2023-10-31	艾莱克特有限责任公司	抗tmem106b抗体及其使用方法
WO2022197877A1 (en)	2021-03-19	2022-09-22	Genentech, Inc.	Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
US20240166738A1 (en)	2021-03-23	2024-05-23	Alector Llc	Anti-tmem106b antibodies for treating and preventing coronavirus infections
WO2022207521A1 (en)	2021-03-30	2022-10-06	F. Hoffmann-La Roche Ag	Protease-activated polypeptides
US20240239895A1 (en)	2021-04-09	2024-07-18	Genentech, Inc.	Combination therapy with a raf inhibitor and a pd-1 axis inhibitor
AR125344A1 (es)	2021-04-15	2023-07-05	Chugai Pharmaceutical Co Ltd	Anticuerpo anti-c1s
CN117529333A (zh)	2021-04-16	2024-02-06	细胞基因公司	对先前进行过干细胞移植的患者的t细胞疗法
TW202305122A (zh)	2021-04-19	2023-02-01	美商建南德克公司	經修飾之哺乳動物細胞
CN117222412A (zh)	2021-04-23	2023-12-12	豪夫迈·罗氏有限公司	Nk细胞接合剂相关的不良反应的预防或减轻
EP4329800A1 (en)	2021-04-30	2024-03-06	F. Hoffmann-La Roche AG	Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
CN117321078A (zh)	2021-04-30	2023-12-29	豪夫迈·罗氏有限公司	针对用抗cd20/抗cd3双特异性抗体和抗cd79b抗体药物缀合物进行组合治疗的给药
US20240218057A1 (en)	2021-05-06	2024-07-04	The Rockefeller University	Neutralizing anti- sars-cov-2 antibodies and methods of use thereof
TW202310876A (zh)	2021-05-12	2023-03-16	美商建南德克公司	使用抗ｃｄ７９ｂ免疫結合物治療瀰漫性大ｂ細胞淋巴瘤之方法
EP4337317A1 (en)	2021-05-14	2024-03-20	Genentech, Inc.	Agonists of trem2
WO2022243261A1 (en)	2021-05-19	2022-11-24	F. Hoffmann-La Roche Ag	Agonistic cd40 antigen binding molecules targeting cea
CN117396599A (zh)	2021-05-21	2024-01-12	基因泰克公司	用于生产目的重组产物的经修饰的细胞
AR126009A1 (es)	2021-06-02	2023-08-30	Hoffmann La Roche	Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
AR126054A1 (es)	2021-06-04	2023-09-06	Chugai Pharmaceutical Co Ltd	Anticuerpos anti-ddr2 y usos de estos
MX2023014563A (es)	2021-06-09	2024-02-08	Hoffmann La Roche	Combinacion de un inhibidor de braf particular (interruptor de paradoja) y un antagonista de union al eje de pd-1 para su uso en el tratamiento de cancer.
JP2024527493A (ja)	2021-06-16	2024-07-25	アレクトルエルエルシー	一価の抗ＭｅｒＴＫ抗体及びその使用方法
JP2024527262A (ja)	2021-06-16	2024-07-24	アレクトルエルエルシー	二重特異性抗ＭｅｒＴＫ及び抗ＰＤＬ１抗体ならびにその使用方法
WO2022263638A1 (en)	2021-06-17	2022-12-22	Centre Hospitalier Universitaire Vaudois (C.H.U.V.)	Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
KR102690141B1 (ko)	2021-06-25	2024-07-30	추가이 세이야쿠 가부시키가이샤	항ctla-4 항체
IL308633A (en)	2021-06-25	2024-01-01	Chugai Pharmaceutical Co Ltd	Use of anti-ctla-4 antibody
BR112023026966A2 (pt)	2021-07-02	2024-03-12	Hoffmann La Roche	Métodos para tratar um indivíduo com melanoma, para alcançar uma resposta clínica, para tratar um indivíduo com linfoma não hodgkin, para tratar uma população de indivíduos com linfoma não hodgkin e para tratar um indivíduo com câncer colorretal metastático
TW202309097A (zh)	2021-07-14	2023-03-01	美商建南德克公司	抗ｃ－ｃ模體趨化因子受體８（ｃｃｒ８）抗體及其使用方法
EP4373576A1 (en)	2021-07-22	2024-05-29	Genentech, Inc.	Brain targeting compositions and methods of use thereof
IL309120A (en)	2021-07-28	2024-02-01	Hoffmann La Roche	Methods and compositions for the treatment of cancer
CN117794953A (zh)	2021-08-03	2024-03-29	豪夫迈·罗氏有限公司	双特异性抗体及使用方法
CN117897409A (zh)	2021-08-13	2024-04-16	基因泰克公司	抗类胰蛋白酶抗体的给药
WO2023021055A1 (en)	2021-08-19	2023-02-23	F. Hoffmann-La Roche Ag	Multivalent anti-variant fc-region antibodies and methods of use
AU2022332303A1 (en)	2021-08-27	2024-02-01	Genentech, Inc.	Methods of treating tau pathologies
JP2024534853A (ja)	2021-08-30	2024-09-26	ジェネンテック，インコーポレイテッド	抗ポリビキチン多重特異性抗体
JPWO2023053282A1 (fi)	2021-09-29	2023-04-06
WO2023056403A1 (en)	2021-09-30	2023-04-06	Genentech, Inc.	Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
KR20240082388A (ko)	2021-10-08	2024-06-10	추가이 세이야쿠 가부시키가이샤	프리필드 시린지 제제의 조제 방법
CN118139648A (zh)	2021-10-14	2024-06-04	豪夫迈·罗氏有限公司	用于治疗癌症的替代的PD1-IL7v免疫缀合物
CA3234731A1 (en)	2021-10-14	2023-04-20	F. Hoffmann-La Roche Ag	New interleukin-7 immunoconjugates
EP4419558A1 (en)	2021-10-19	2024-08-28	Alector LLC	Anti-cd300lb antibodies and methods of use thereof
TW202325742A (zh)	2021-11-01	2023-07-01	瑞士商赫孚孟拉羅股份公司	使用 HLA-A2/WT1 x CD3 雙特異性抗體及 4-1BB (CD137) 促效劑治療癌症
JP2024543404A (ja)	2021-11-10	2024-11-21	エフ．ホフマン－ラロシュアーゲー	親水性アザジベンゾシクロオクチン誘導体およびこれらの親水性アザジベンゾシクロオクチン誘導体との無金属クリック反応
WO2023086807A1 (en)	2021-11-10	2023-05-19	Genentech, Inc.	Anti-interleukin-33 antibodies and uses thereof
EP4180518A1 (en)	2021-11-12	2023-05-17	Istituto Europeo di Oncologia S.r.l.	T cells and uses thereof
WO2023088889A1 (en)	2021-11-16	2023-05-25	Apogenix Ag	CD137 ligands
WO2023088876A1 (en)	2021-11-16	2023-05-25	Apogenix Ag	Multi-specific immune modulators
CA3236006A1 (en)	2021-11-16	2023-05-25	Genentech, Inc.	Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
EP4183800A1 (en)	2021-11-19	2023-05-24	Medizinische Hochschule Hannover	Novel sars-cov-2 neutralizing antibodies
AR127887A1 (es)	2021-12-10	2024-03-06	Hoffmann La Roche	Anticuerpos que se unen a cd3 y plap
CN118541382A (zh)	2021-12-14	2024-08-23	豪夫迈·罗氏有限公司	使用HLA-A2/MAGE-A4 x CD3双特异性抗体和4-1BB(CD137)激动剂治疗癌症
AU2022411573A1 (en)	2021-12-17	2024-06-27	Shanghai Henlius Biologics Co., Ltd.	Anti-ox40 antibodies and methods of use
EP4448575A2 (en)	2021-12-17	2024-10-23	Dana-Farber Cancer Institute, Inc.	Platform for antibody discovery
WO2023109900A1 (en)	2021-12-17	2023-06-22	Shanghai Henlius Biotech, Inc.	Anti-ox40 antibodies, multispecific antibodies and methods of use
CA3241395A1 (en)	2021-12-17	2023-06-22	Barbel SCHROFELBAUER	Antibodies and uses thereof
CR20240246A (es)	2021-12-20	2024-07-19	Hoffmann La Roche	Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
TW202340251A (zh)	2022-01-19	2023-10-16	美商建南德克公司	抗ｎｏｔｃｈ２抗體及結合物及其使用方法
AR128330A1 (es)	2022-01-26	2024-04-17	Genentech Inc	Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
AR128331A1 (es)	2022-01-26	2024-04-17	Genentech Inc	Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
WO2023147399A1 (en)	2022-01-27	2023-08-03	The Rockefeller University	Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
EP4223302A1 (en)	2022-02-08	2023-08-09	Universität Heidelberg	Oncolytic measles virus encoding a bike and methods of use thereof in treating cancer
CN119173278A (zh)	2022-03-10	2024-12-20	维硕公司	抗体偶联药物及其用途
MX2024011468A (es)	2022-03-23	2024-09-25	Hoffmann La Roche	Tratamiento conjunto de un anticuerpo biespecifico anti-cd20/anti-cd3 y quimioterapia.
TW202402790A (zh)	2022-03-25	2024-01-16	英商梅迪繆思有限公司	減少呼吸系統感染之方法
KR20240163119A (ko)	2022-03-25	2024-11-18	상하이 헨리우스 바이오테크, 인크.	항-msln 항체 및 사용 방법
EP4499229A1 (en)	2022-03-28	2025-02-05	F. Hoffmann-La Roche AG	Interferon gamma variants and antigen binding molecules comprising these
AU2022450448A1 (en)	2022-04-01	2024-10-10	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
CN119384432A (zh)	2022-04-13	2025-01-28	基因泰克公司	治疗性蛋白质的药物组合物和使用方法
TW202404637A (zh)	2022-04-13	2024-02-01	瑞士商赫孚孟拉羅股份公司	抗ｃｄ２０／抗ｃｄ３雙特異性抗體之醫藥組成物及使用方法
CN119487063A (zh)	2022-04-29	2025-02-18	博闻生物有限责任公司	双特异性抗体以及治疗眼部疾病的方法
EP4514844A1 (en)	2022-04-29	2025-03-05	Broadwing Bio LLC	Complement factor h related 4-specific antibodies and uses thereof
EP4514470A1 (en)	2022-04-29	2025-03-05	Broadwing Bio LLC	Angiopoietin-related protein 7-specific antibodies and uses thereof
KR20250006932A (ko)	2022-05-03	2025-01-13	제넨테크, 인크.	항-Ly6E 항체, 면역접합체 및 이들의 용도
KR20250008774A (ko)	2022-05-11	2025-01-15	셀진 코포레이션	T 세포 요법 및 그의 생산과 관련된 방법 및 용도
IL316738A (en)	2022-05-11	2024-12-01	Genentech Inc	Dosage for treatment with anti-FCRH5/anti-CD3 bispecific antibodies
WO2023218431A1 (en)	2022-05-13	2023-11-16	BioNTech SE	Rna compositions targeting hiv
WO2023230548A1 (en)	2022-05-25	2023-11-30	Celgene Corporation	Method for predicting response to a t cell therapy
US20230416412A1 (en)	2022-05-31	2023-12-28	Hoffmann-La Roche Inc.	Prevention or mitigation of t-cell engaging agent-related adverse effects
KR20250022049A (ko)	2022-06-07	2025-02-14	제넨테크, 인크.	항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법
CN119585308A (zh)	2022-07-13	2025-03-07	基因泰克公司	针对用抗fcrh5/抗cd3双特异性抗体进行的治疗的给药
TW202413433A (zh)	2022-07-19	2024-04-01	美商建南德克公司	用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
IL317637A (en)	2022-07-22	2025-02-01	Genentech Inc	Anti-STEAP1 antigen binding molecules and their uses
AU2023312054A1 (en)	2022-07-22	2025-01-23	Bristol-Myers Squibb Company	Antibodies binding to human pad4 and uses thereof
AU2023314807A1 (en)	2022-07-29	2025-03-06	Alector Llc	Transferrin receptor antigen-binding domains and uses therefor
IL317690A (en)	2022-07-29	2025-02-01	Alector Llc	Anti-GPNMB antibodies and methods of using them
WO2024026471A1 (en)	2022-07-29	2024-02-01	Alector Llc	Cd98hc antigen-binding domains and uses therefor
WO2024038095A1 (en)	2022-08-16	2024-02-22	Iome Bio	NOVEL ANTI-RGMb ANTIBODIES
WO2024049949A1 (en)	2022-09-01	2024-03-07	Genentech, Inc.	Therapeutic and diagnostic methods for bladder cancer
WO2024056861A1 (en)	2022-09-15	2024-03-21	Avidicure Ip B.V.	Multispecific antigen binding proteins for stimulating nk cells and use thereof
WO2024068705A1 (en)	2022-09-29	2024-04-04	F. Hoffmann-La Roche Ag	Protease-activated polypeptides
WO2024068996A1 (en)	2022-09-30	2024-04-04	Centre Hospitalier Universitaire Vaudois (C.H.U.V.)	Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
WO2024077239A1 (en)	2022-10-07	2024-04-11	Genentech, Inc.	Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
TW202430211A (zh)	2022-10-10	2024-08-01	瑞士商赫孚孟拉羅股份公司	Ｇｐｒｃ５ｄｔｃｂ及ｉｍｉｄ之組合療法
TW202423970A (zh)	2022-10-10	2024-06-16	瑞士商赫孚孟拉羅股份公司	Ｇｐｒｃ５ｄｔｃｂ及ｃｄ３８抗體之組合療法
TW202423969A (zh)	2022-10-10	2024-06-16	瑞士商赫孚孟拉羅股份公司	Ｇｐｒｃ５ｄｔｃｂ及蛋白酶體抑制劑之組合療法
WO2024086796A1 (en)	2022-10-20	2024-04-25	Alector Llc	Anti-ms4a4a antibodies with amyloid-beta therapies
WO2024091991A1 (en)	2022-10-25	2024-05-02	Genentech, Inc.	Therapeutic and diagnostic methods for multiple myeloma
WO2024094741A1 (en)	2022-11-03	2024-05-10	F. Hoffmann-La Roche Ag	Combination therapy with anti-cd19/anti-cd28 bispecific antibody
WO2024102734A1 (en)	2022-11-08	2024-05-16	Genentech, Inc.	Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
WO2024100170A1 (en)	2022-11-11	2024-05-16	F. Hoffmann-La Roche Ag	Antibodies binding to hla-a*02/foxp3
TW202440623A (zh)	2022-11-28	2024-10-16	美商艾洛基因醫療公司	靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途
WO2024115349A1 (en)	2022-11-29	2024-06-06	F. Hoffmann-La Roche Ag	Improved cancer immunotherapy
WO2024129594A1 (en)	2022-12-12	2024-06-20	Genentech, Inc.	Optimizing polypeptide sialic acid content
WO2024137589A2 (en)	2022-12-20	2024-06-27	Genentech, Inc.	Methods of treating pancreatic cancer with a pd-1 axis binding antagonist and an rna vaccine
WO2024141955A1 (en)	2022-12-28	2024-07-04	BioNTech SE	Rna compositions targeting hiv
WO2024148232A2 (en)	2023-01-06	2024-07-11	Alector Llc	Anti-il18 binding protein antibodies and methods of use thereof
WO2024149821A1 (en)	2023-01-13	2024-07-18	F. Hoffmann-La Roche Ag	Treatment of cancer using a hla-a2/wt1 x cd3 bispecific antibody and venetoclax/azacitidine
US20240360229A1 (en)	2023-01-18	2024-10-31	Genentech, Inc.	Multispecific antibodies and uses thereof
WO2024156672A1 (en)	2023-01-25	2024-08-02	F. Hoffmann-La Roche Ag	Antibodies binding to csf1r and cd3
WO2024163009A1 (en)	2023-01-31	2024-08-08	Genentech, Inc.	Methods and compositions for treating urothelial bladder cancer
TW202436339A (zh)	2023-01-31	2024-09-16	瑞士商赫孚孟拉羅股份公司	治療選自非小細胞肺癌或三陰性乳癌的癌症之用途
WO2024191785A1 (en)	2023-03-10	2024-09-19	Genentech, Inc.	Fusions with proteases and uses thereof
WO2024188965A1 (en)	2023-03-13	2024-09-19	F. Hoffmann-La Roche Ag	Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
WO2024188966A1 (en)	2023-03-13	2024-09-19	F. Hoffmann-La Roche Ag	Treatment of cancer using an anti-hla-g/anti-cd3 bispecific antibody and a 4‑1bb (cd137) agonist
US20240327522A1 (en)	2023-03-31	2024-10-03	Genentech, Inc.	Anti-alpha v beta 8 integrin antibodies and methods of use
WO2024211234A1 (en)	2023-04-05	2024-10-10	Sorrento Therapeutics, Inc.	Antibody-drug conjugates and uses thereof
WO2024211236A2 (en)	2023-04-05	2024-10-10	Sorrento Therapeutics, Inc.	Antibody-drug conjugates and uses thereof
WO2024211235A1 (en)	2023-04-05	2024-10-10	Sorrento Therapeutics, Inc.	Antibody-drug conjugates and uses thereof
WO2024215948A1 (en)	2023-04-12	2024-10-17	Fusion Pharmaceuticals Inc.	Steap2–targeted compounds and use thereof
WO2024220546A2 (en)	2023-04-17	2024-10-24	Peak Bio, Inc.	Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
WO2024223769A1 (en)	2023-04-26	2024-10-31	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	H3 histone mutein binding compounds
WO2024226794A1 (en)	2023-04-26	2024-10-31	The Trustees Of Indiana University	Composition and methods for treatment of spinal cord injury and traumatic brain injury
WO2024227154A1 (en)	2023-04-28	2024-10-31	Broadwing Bio Llc	Complement component 3 (c3)-specific antibodies and uses thereof
TW202448949A (zh)	2023-05-05	2024-12-16	美商建南德克公司	用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
WO2024231320A1 (en)	2023-05-08	2024-11-14	F. Hoffmann-La Roche Ag	Targeted interferon alpha fusion proteins and methods of use
WO2024233646A1 (en)	2023-05-10	2024-11-14	Genentech, Inc.	Methods and compositions for treating cancer
WO2024238537A1 (en)	2023-05-16	2024-11-21	F. Hoffmann-La Roche Ag	Pd-1 -regulated il-2 immunocytokine and uses thereof
WO2024238934A1 (en)	2023-05-18	2024-11-21	Clade Therapeutics, Inc.	Inhibiting natural killer cell cytotoxicity against cell therapies
TW202448933A (zh)	2023-05-31	2024-12-16	美商建南德克公司	用抗轉化生長因子β３抗體治療ＴＧＦβ相關病症之方法
WO2024246083A1 (en)	2023-06-01	2024-12-05	F. Hoffmann-La Roche Ag	Bispecific antibodies targeting bcma and cd28
WO2024246086A1 (en)	2023-06-01	2024-12-05	F. Hoffmann-La Roche Ag	Immunostimulatory antigen binding molecules that specifically bind to bcma
WO2024261013A1 (en)	2023-06-21	2024-12-26	F. Hoffmann-La Roche Ag	Combination therapy with fap-targeted lymphotoxin beta receptor agonists
WO2024263845A1 (en)	2023-06-22	2024-12-26	Genentech, Inc.	Treatment of multiple myeloma
US20250011450A1 (en)	2023-06-22	2025-01-09	Genentech, Inc.	Antibodies and uses thereof
WO2024263195A1 (en)	2023-06-23	2024-12-26	Genentech, Inc.	Methods for treatment of liver cancer
WO2024263904A1 (en)	2023-06-23	2024-12-26	Genentech, Inc.	Methods for treatment of liver cancer
WO2025024265A1 (en)	2023-07-21	2025-01-30	Bristol-Myers Squibb Company	Methods of assessing citrullination and activity of pad4 modulators
WO2025021838A1 (en)	2023-07-26	2025-01-30	F. Hoffmann-La Roche Ag	Antibodies binding to cd3
WO2025027579A2 (en)	2023-08-03	2025-02-06	BioNTech SE	Rna compositions targeting hiv
WO2025027576A2 (en)	2023-08-03	2025-02-06	BioNTech SE	Rna compositions targeting hiv
WO2025034806A1 (en)	2023-08-08	2025-02-13	Wisconsin Alumni Research Foundation	Single-domain antibodies and variants thereof against fibroblast activation protein
WO2025032069A1 (en)	2023-08-09	2025-02-13	F. Hoffmann-La Roche Ag	Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032071A1 (en)	2023-08-09	2025-02-13	F. Hoffmann-La Roche Ag	Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025042786A1 (en)	2023-08-18	2025-02-27	Flagship Pioneering Innovations Vi, Llc	Compositions comprising circular polyribonucleotides and uses thereof
WO2025049277A1 (en)	2023-08-25	2025-03-06	Genentech, Inc.	Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist
WO2025056655A1 (en)	2023-09-14	2025-03-20	F. Hoffmann-La Roche Ag	Antibody formulation
US12122842B1 (en)	2023-09-27	2024-10-22	R&D Systems, Inc.	Human CD30-specific binding proteins and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4536518A (en) *	1979-11-01	1985-08-20	Pfizer Inc.	Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4556676A (en) *	1979-11-01	1985-12-03	Pfizer Inc.	Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine

1991
- 1991-07-11 GB GB919114948A patent/GB9114948D0/en active Pending
1992
- 1992-07-03 JP JP5501952A patent/JP2563754B2/ja not_active Expired - Fee Related
- 1992-07-03 DK DK92914659.5T patent/DK0595851T3/da active
- 1992-07-03 AT AT92914659T patent/ATE132848T1/de not_active IP Right Cessation
- 1992-07-03 EP EP92914659A patent/EP0595851B1/en not_active Expired - Lifetime
- 1992-07-03 US US08/178,240 patent/US5442116A/en not_active Expired - Fee Related
- 1992-07-03 WO PCT/EP1992/001496 patent/WO1993001161A1/en active IP Right Grant
- 1992-07-03 CA CA002109818A patent/CA2109818C/en not_active Expired - Fee Related
- 1992-07-03 ES ES92914659T patent/ES2082481T3/es not_active Expired - Lifetime
- 1992-07-03 DE DE69207601T patent/DE69207601T2/de not_active Expired - Fee Related
- 1992-07-09 PT PT100673A patent/PT100673B/pt not_active IP Right Cessation
- 1992-07-10 IE IE922249A patent/IE71029B1/en not_active IP Right Cessation
1994
- 1994-01-10 FI FI940105A patent/FI112209B/fi not_active IP Right Cessation
1996
- 1996-02-28 GR GR960400546T patent/GR3019122T3/el unknown

Also Published As

Publication number	Publication date
ES2082481T3 (es)	1996-03-16
GB9114948D0 (en)	1991-08-28
JP2563754B2 (ja)	1996-12-18
ATE132848T1 (de)	1996-01-15
IE71029B1 (en)	1997-01-15
WO1993001161A1 (en)	1993-01-21
EP0595851A1 (en)	1994-05-11
FI940105A0 (fi)	1994-01-10
DE69207601D1 (de)	1996-02-22
CA2109818A1 (en)	1993-01-12
US5442116A (en)	1995-08-15
JPH06509079A (ja)	1994-10-13
PT100673A (pt)	1993-09-30
GR3019122T3 (fi)	1996-05-31
IE922249A1 (en)	1993-01-13
DK0595851T3 (da)	1996-02-12
DE69207601T2 (de)	1996-05-23
PT100673B (pt)	1999-07-30
EP0595851B1 (en)	1996-01-10
FI112209B (fi)	2003-11-14
CA2109818C (en)	2003-01-21

Publication	Publication Date	Title
FI940105L (fi)	1994-01-10	Menetelmä sertraliinivälituotteiden valmistamiseksi
FI951596L (fi)	1995-04-04	Menetelmä 10-desasetyylibakkatiini-III:n saamiseksi
FI20001900L (fi)	2000-08-29	Välituotteet
FI962069L (fi)	1996-05-15	Menetelmä karpolaktaamin valmistamiseksi
FI951590L (fi)	1995-04-04	Menetelmä 10-desasetyylibakkatiini III:n valmistamiseksi
DK0533752T3 (da)	1998-06-02	Forbedret syntesefremgangsmåde
FI941135L (fi)	1994-03-10	Uusi biomenetelmä 7-ADCA:n valmistamiseksi
NO921218L (no)	1992-09-29	Reseptor-rensemetode
FI942907L (fi)	1994-06-17	Menetelmä lipaasin valmistamiseksi
FI921621L (fi)	1992-10-13	Sprutmetod foer braensle
FI940106L (fi)	1994-01-10	Menetelmä sertraliinin valmistamiseksi
FI955800L (fi)	1995-12-01	Menetelmä aminoalkyyliganidiinien valmistamiseksi
FI940280L (fi)	1994-01-20	Menetelmä demetyyliepypodofyylilotoksiinin valmistamiseksi
DE69128667D1 (de)	1998-02-19	Positionsbestimmungsmethode
FI931850L (fi)	1994-10-24	Menetelmä välituotteen valmistamiseksi
FI964001L (fi)	1996-10-04	Menetelmä 7-trialkyylisilyylibakkatiini III:n valmistamiseksi
FI962250L (fi)	1996-05-29	Menetelmä kiraalisen tetralonin valmistamiseksi
DE69219741D1 (de)	1997-06-19	Hydrolisylierungsverfahren
ITTO911046A1 (it)	1992-06-27	Metodo di sgrassaggio-pulitura
DE4290817T1 (de)	1994-02-17	Stellantrieb-Servo-Kompensationsverfahren
DK0512652T3 (da)	1995-09-25	Hydrodecykliseringsfremgangsmåde
FI941397L (fi)	1994-09-26	Menetelmä metyyliformiaatin valmistamiseksi
FI963018L (fi)	1996-07-30	Menetelmä gammapyronien valmistamiseksi
FI910366L (fi)	1991-07-27	Menetelmä deoksimulundokandiinin valmistamiseksi
FI942989L (fi)	1994-06-21	Isomerointimenetelmä

Legal Events

Date	Code	Title	Description
2008-01-31	MA	Patent expired